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These data demonstrate that lncRNAs can function as highly cell-type specific effectors of extracellular
cues to control immunological processes that require rapid and strict regulation.
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ABSTRACT

LONG NON-CODING RNA REGULATION OF IMMUNE HOMEOSTASIS
Jonathan J. Kotzin

Jorge Henao-Mejia
E. John Wherry

The immune system is comprised of diverse cell types that work together to
protect the host from infection and maintain tissue homeostasis. To achieve this
complex balance, extracellular cues determine highly specific epigenetic
landscapes and transcriptional profiles of each immune cell subtype. New
evidence indicates that long non-coding RNAs (lncRNAs) play critical roles in
epigenetic and transcriptional regulation in mammals. Here we identify the lncRNA
Morrbid, and examine its role in immune function. In Chapter 2, we assess the
function of Morrbid at homeostasis and describe its role in finely tuning the lifespan
of short-lived myeloid cells. In Chapter 3, we examine Morrbid under inflammatory
conditions and illustrate its role in restraining CD8 T cell responses following viral
infection. These data demonstrate that lncRNAs can function as highly cell-type
specific effectors of extracellular cues to control immunological processes that
require rapid and strict regulation.
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Chapter 1 : Introduction
A relatively recent observation in biology is that while the number of protein
coding genes has remained generally stable across multicellular organisms, the
quantity of non-coding DNA has increased in parallel with the developmental
complexity of organisms (Taft et al., 2007). This finding suggests that non-coding
regulation of protein-coding genes likely determines phenotypic complexity (Taft
et al., 2007). In support of this hypothesis, a number of high-throughput
sequencing projects have recently shown that a large proportion of the mammalian
non-coding genome comprises a network of regulatory elements such as
promoters, enhancers, and super-enhancers (Derrien et al., 2012; ENCODE
Project Consortium, 2012; Hnisz et al., 2013). Strikingly, these studies also
showed, in one particular cell type, that nearly 70% of the human non-coding
genome is transcribed. The function of the majority of these non-coding transcripts
is unknown; nevertheless, several classes of non-coding RNAs have been found
to contribute to the transcriptional and epigenetic regulation of gene expression
programs. Among these classes of non-coding RNAs, long non-coding RNAs
(lncRNAs) are highly abundant and have been a subject of great interest in recent
years.
A diverse group of cells from the innate and adaptive immune system
orchestrate protective immune responses to combat infections while preventing
the deleterious consequences of prolonged inflammation. The highly-specialized
functions of each of these immune cell types are determined by their unique
1

transcriptional programs. While much is known about how transcription factors and
different extracellular cues regulate the development and function of innate and
adaptive immune cells, our knowledge regarding the roles of lncRNAs in the
immune system is limited. A growing body of evidence indicates that lncRNAs are
expressed in a more cell type-specific manner than protein-coding genes and are
rapidly induced by unique tissue-derived and environmental signals (Cabili et al.,
2011; Guttman et al., 2010). As such, these molecules have started to emerge as
highly cell type-specific regulators of gene expression programs in the immune
system.

The regulatory role of lncRNAs
LncRNAs accomplish a diverse range of biological functions through an
equally diverse range of molecular mechanisms (Rinn and Chang, 2012). For
example, it has been demonstrated that lncRNA molecules themselves can directly
interact with proteins, DNA, or other RNAs to exert their functions. Nevertheless,
not all biologically-active lncRNA loci depend on the function of the RNA molecule
itself. The biological mechanisms of lncRNAs loci can be distilled into 4 different
categories: (i) lncRNA loci in which the RNA molecule itself is functional, (ii)
lncRNA loci in which the act of transcription, but not the lncRNA molecule, has a
functional role, (iii) lncRNAs that represent proxy signals for active cis-regulatory
elements, and (iv) lncRNAs that encode short bioactive peptides.

2

LncRNAs dependent on intrinsic RNA function
The first lncRNAs were characterized by demonstrating direct biological
activity of the RNA molecule itself (Pandey et al., 2008; Penny et al., 1996; Rinn
et al., 2007), and this remains the gold standard for characterizing lncRNA loci.
Functional lncRNAs can localize to the nucleus or cytosol to specifically interact
with proteins, DNA, or other RNAs to perform their molecular functions. The
sequence constraints for RNA folding and structure are more lenient than those
for protein folding, which has likely helped facilitate the evolution of such
mechanistically versatile lncRNA molecules. The recent development of novel
RNA-centric tools that directly test lncRNA structure, localization, and
interactomes has paved the way for our understanding of the mechanisms of
action of lncRNAs. Conceptually, we group functional lncRNAs into two classes:
those that serve as inhibitors and those that serve as facilitators of binding partner
interactions.
Class I functional lncRNAs: Inhibitors – keeping things apart
Many protein-protein interactions conform to a classic molecular decoy
archetype, wherein the decoy molecule binds to and inhibits one partner in an
interaction. A classic example of a molecular decoy is the non-signaling interleukin
1 receptor type 2 (IL1R2), which binds the cytokine IL-1β and prevents it from
signaling through its normal receptor (Colotta et al., 1993). Here we expand upon
the classic molecular decoy archetype to include lncRNA-mediated processes in
which factors are inhibited from interacting with one another (Fig. 1.1a). This class
clearly applies to lncRNAs that act as sinks for microRNAs, such as the lncRNA
3

Phosphatase and Tensin Homolog Pseudogene 1 (PTENP1), whose 3’ UTR binds
the same set of miRNAs sequences that normally target the tumor-suppressor
gene PTEN (Poliseno et al., 2010). In addition, this class also includes lncRNAs
that specifically inhibit classical protein-protein interactions such as the lncRNA
lnc-DC (Wang et al., 2014). Lnc-DC regulates the differentiation and activation
profile of dendritic cells (DCs) in humans by binding STAT3 in the cytoplasm and
preventing its dephosphorylation and inactivation by the tyrosine phosphatase
SHP1 (Wang et al., 2014). Additionally, this inhibitory class includes lncRNAs that
block protein-DNA interactions, such as pseudogene-derived lncRNA Lethe
(Rapicavoli et al., 2013). Lethe physically associates with the NF-kB p65 (RelA)
subunit and directly or indirectly blocks its recruitment to the promoters of certain
immune genes such as IL6 and IL8 (Rapicavoli et al., 2013). Of note, lncRNAs can
impact these processes rapidly, as lncRNAs are not dependent on translation.
Together, these studies indicate that by blocking key DNA, RNA, or protein
interactions, lncRNAs can exert rapid potent biological outcomes in the immune
system.
Class II of functional lncRNAs: Facilitators – bringing things together
LncRNAs have also been described to form complexes with protein, RNA,
and/or DNA, and facilitate the interaction of specific binding partners. This class of
RNA-dependent mechanism includes lncRNAs that serve as “scaffolds” or
“guides” (Fig. 1.1b). “Scaffold” lncRNAs can function as molecular platforms upon
which other DNA, RNA, and protein molecules can assemble. For example, the
lncRNA RMRP facilitates an interaction between the nuclear receptor RAR-related
4

orphan receptor gamma (RORγt) and DEAD-box protein 5 (DDX5) (Huang et al.,
2015). This RORγt-DDX5 interaction is necessary for transcriptional co-activation
of certain T helper 17 (Th17) genes (Huang et al., 2015). On the other hand,
lncRNAs that serve as “guides” can bind other DNA, RNA, and protein molecules
and target their localization to induce a specific biological function. For example,
X-inactive specific transcript (Xist), as its name implies, involved in the silencing of
the second X chromosome in female placental mammals. Xist is expressed by
and coats the inactive X chromosome from which it is transcribed by binding and
promoting the recruitment of multiple repressive factors including Polycomb,
SHARP, and others (Cerase et al., 2015; McHugh et al., 2015; Zhao et al., 2008).
The scaffold and guide classes are closely related. For example, a lncRNA
can bind a protein and be required for that protein’s localization to a specific
genomic location; yet, this localization may be dependent on an additional protein
associated with the lncRNA. Thus this lncRNA would be guiding the protein of
interest to a specific location through its scaffolding activity. The distinction of the
scaffold and guide classes is typically determined by whether the lncRNAs
attributed biological function is directly or indirectly dependent on localization. For
instance, Xist has the ability to associate with many different protein complexes;
nevertheless, its function is predominately dependent on the direct and indirect
recruitment of these complexes to the inactive X chromosome. As such, for
simplicity, Xist is typically categorized as a lncRNA guide. Of note, the general
model of lncRNA direct protein recruitment is complicated by no known proteinbinding motifs within lncRNAs and little quantification data of RNA binding
5

specificity (reviewed in (Davidovich and Cech, 2015)). Future studies on lncRNA
motifs and structure are needed to better understand how lncRNAs interact with
specific proteins and how lncRNAs localize to specific sites.
Transcription across the lncRNA has a functional role
As previously discussed, lncRNAs demonstrate exquisite cell type-specific
expression and many are responsive to specific extracellular cues. Given the strict
regulation of lncRNA biogenesis and that many lncRNAs impact the expression of
neighboring genes, it has been suggested that the process of transcription and/or
splicing of lncRNAs may alter the expression of spatially proximal genes through
the recruitment of specific protein factors (Ebisuya et al., 2008; Sleutels et al.,
2002; Swiezewski et al., 2009) (Fig. 1.1c). This concept was recently dissected in
further detail through the study of the protein coding gene Sfmbt2 and its
neighboring lncRNA Blustr. The authors found that Sfmbt2 is upregulated by the
splicing and transcription of Blustr, in a mechanism independent of the sequence
of Blustr but likely to involve the recruitment of polymerases and chromatinmodifiers (Engreitz et al., 2016). By elegantly inserting a synthetic polyadenylation
(polyA) sequence at different places within this locus in vitro, these effects were
found to be dependent on the length of transcription across the Blustr locus
(Engreitz et al., 2016). Additionally, promoter-proximal splice sites are known to
enhance transcription, and deletion of this site of Blustr also impacted Sfmbt2
transcription (Engreitz et al., 2016). In parallel, Anderson and colleagues
demonstrated in vivo that the heart development regulator Hand2 is controlled in
cis by the lncRNA upperhand (Uph), but that this control is independent of the
6

sequence of Uph (Anderson et al., 2016). Of note, the authors found that
transcription of Uph was required to maintain the chromatin state of a cardiac
super-enhancer-like element within the Uph locus (Anderson et al., 2016).
Although it is not clear mechanistically how transcription and/or splicing recruit
critical regulatory factors to coordinate the expression of genes in cis, these studies
clearly demonstrate that lncRNA biogenesis itself can impact proximal genes in a
transcript and sequence independent manner.
LncRNAs as proxy signals for cis-regulatory elements
The promoters of many lncRNA loci are conserved across species and have
enhancer chromatin signatures, suggesting that certain lncRNA promoters may
function as cis-acting enhancer elements, and that transcription is simply a
byproduct of this activity (Engreitz et al., 2016; Necsulea and Kaessmann, 2014).
Given that lncRNA loci frequently contain or are in close proximity to important
regulatory DNA elements, the production of lncRNAs from these loci can delineate
critical cis-regulatory DNA elements within these loci (Fig. 1.1d). For example,
mapping of RNA polymerase II using Chromatin Interaction Analysis with PairedEnd-Tag sequencing (ChIA-PET) revealed strong genome-wide promotercentered intergenic interactions, suggesting that promoters of coding and noncoding genes may have dual functions as enhancers (Li et al., 2012). Therefore,
certain lncRNA transcripts may arise as non-functional by-products, yet they may
serve as proxy signals of the activity of important regulatory elements. In another
set of studies, deletion of the lncRNA down-stream of Cdkn1b (Lockd) locus was
found to impact the transcription of its neighboring gene Cdkn1b; however, pre7

mature polyadenylation of Lockd had no impact on Cdkn1b transcription (Paralkar
et al., 2016). The Lockd promoter was found to have many enhancer-like features
suggesting that this lncRNA locus may indeed function through DNA elements
within its promoter and that the RNA transcript produced from this locus only marks
this important DNA regulatory element (Paralkar et al., 2016). Importantly, this
class of lncRNA is not limited to lncRNAs that reflect the activity of cis-regulatory
elements within their promoter. Recently, it was observed that the lncRNA Rroid is
specifically expressed in group 1 innate lymphoid cells (ILCs), and demarks critical
cis-regulator elements important for the maturation, function, and lineage identity
of these cells while being dispensable for the development and homeostasis of
closely related ILC2s and ILC3s (Mowel et al., 2017a). We predict that many celltype specific lncRNAs will demarcate critical cis-regulatory elements that control
highly specialized processes in immune cells.
LncRNAs encoding open reading frames
Important recent work has demonstrated that certain ribosome-associated
lncRNAs which, by definition, were annotated as non-coding are now reported to
code for short peptides with biological function (Anderson et al., 2015; Bazzini et
al., 2014; Nelson et al., 2016). In a human myelogenous leukemia cell line,
approximately 70% of cytoplasmic lncRNAs have more than 50% of their
cytoplasmic copies associated with polysome fractions (Carlevaro-Fita et al.,
2016). It has been suggested that the rate of degradation of these lncRNA
transcripts is dependent on their association with the ribosome. Nevertheless,
high-throughput ribosome profiling analysis of all cytoplasmic RNAs has
8

demonstrated that open reading frames (ORFs) are more diverse than the
traditional start-to-stop codon variety (Brar and Weissman, 2015). There exist
regulatory polycistronic upstream ORFs that impact the translation of downstream
ORFs, small independent ORFs that encode bona fide function proteins (polished
rice and myoregulin; (Anderson et al., 2015; Kondo et al., 2010)), and ORFs with
non-cannonical start or stop codons. Whether the cryptic translation events of
ribosome associated lncRNAs in the immune system have meaningful biological
function has yet to be determined.

Figure 1.1. Mechanisms of long non-coding RNA (lncRNA) action.
a) lncRNA mechanisms that depend on the RNA molecule itself include lncRNA–RNA,
lncRNA–protein, and lncRNA–DNA-based mechanisms. For example, PTENP1 encodes
miRNA target sequences shared by PTEN and acts as a ‘sponge’ for miRNAs targeting

9

PTEN (left). lnc-DC interacts directly with the protein STAT3 and blocks its
dephosphorylation by the phosphatase SHP-1 (middle). lncRNA Lethe hinders the
recruitment of NF-kB p65 subunit to its target DNA sequences (right). b) lncRNAs can
activate gene expression by acting as scaffolds for interactions between other proteins,
such as lncRNA RMRP (left), or as guides to direct the recruitment of chromatin-modifying
complexes to neighboring genes, such as NeST (right). c) The act of lncRNA transcription
can intrinsically account for the activity of some lncRNA loci. Transcription across the
lncRNA Blustr directly promotes transcription of its neighboring gene Sfmbt2. d) Some
lncRNAs may not regulate transcription of their target genes, but instead act as a proxy
signals for important DNA regulatory elements embedded within the lncRNA locus. Figure
from Mowel and Kotzin et al. 2017.
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The balance of protective immunity and immunopathology
To quickly combat bacterial, fungal, or viral infections, the human body
rapidly deploys millions of myeloid cells (Manz and Boettcher, 2014). Comprised
of neutrophils, monocytes, macrophages, eosinophils, and basophils, myeloid
cells are typically the first responders to all types of pathogens. These cells use
invariant pattern recognition receptors such as toll–like receptors (TLRs) to
recognize pathogen associated molecular patters (PAMPs) and host damage
associated molecular patterns (DAMPs) (Tang et al., 2012). PAMPs and DAMPs
prime and license these cells to perform their anti-pathogen effector functions,
which include the production of highly potent proteases, reactive oxygen species,
and cytokines (Tang et al., 2012). Importantly, these myeloid effector products not
only act on the pathogen, but can also cause collateral damage to surrounding
host tissue (Kruger et al., 2015). As such, this myeloid anti-pathogen response is
typically short-lived, and largely functions to keep the infection in check until more
specialized immune cells, such as T cells and B cells, can be primed by myeloid
cells to more specifically target the pathogen (Janssen et al., 2016). Given the
large number of myeloid cells and their capacity to cause host tissue damage, their
lifespans must be strictly regulated to balance protective immunity with
immunopathology.
Short-lived myeloid cells
Myeloid cells are typically short-lived in the circulation under homeostatic
conditions. In particular, neutrophils, eosinophils and “classical” monocytes, are
the shortest lived circulating myeloid cells, and represent approximately 70% of all
11

blood leukocytes. When labeled ex-vivo and reintroduced into the circulation,
human neutrophils have a half-life of approximately 8 hours (Dancey et al., 1976),
which closely mirrors the 8-10 hour half-life of in vivo labeled neutrophils in mice
(Basu et al., 2002). A more recent in vivo labeling approach in humans using
deuterium-labeled glucose suggests that human neutrophil lifespan may be
several fold longer than originally appreciated (Pillay et al., 2010). Nevertheless,
deuterium can label bone marrow progenitors and result in the overestimation of
neutrophil longevity, not to mention that independent reanalysis of these data and
an additional cohort of subjects support a relatively short neutrophil in vivo half-life
of 13-19 hours (Lahoz-Beneytez et al., 2016). To better understand human
neutrophil function, these discrepancies in lifespan will need to be addressed;
however, in the context of either proposed lifespan, neutrophils are still one of the
shortest lived immune cells in the body. Similarly, the reported half lives of blood
eosinophils and “classical” monocytes are approximately 18 hours, and 8 hours,
respectively (Farahi et al., 2012; Steinbach et al., 1979; Yona et al., 2013). Given
the prodigious quantity of these three cell types in circulating blood, minor
variations in the rate of death of these cells would have a profound impact on their
circulating cell numbers. For example, in response to a pathogen, increasing the
survival of these cells would allow the host to rapidly accumulate millions of these
potent effectors. On the other hand, an aberrant or prolonged increase in the
survival of these cells would allow these cells to excessively accumulate and
contribute to host tissue damage and inflammatory disease.

12

In concordance with the finely tuned lifespan of these potent short-lived
myeloid cells, all of these cells types are not only well known to be critical for
protective immunity, but are also associated with many different types of
autoinflammation. Neutrophils are the first cells to arrive at sites of infection and
are the predominant phagocytes of circulating blood (Kolaczkowska and Kubes,
2013); yet, several chronic inflammatory diseases are characterized by sustained
influx of neutrophils, such as chronic obstructive pulmonary disease, nephritis,
SLE, and cardiovascular diseases (Frangogiannis et al., 2002; Hoenderdos and
Condliffe, 2013; Kessenbrock et al., 2009; Libby et al., 2002). “Classical”
monocytes are also rapidly recruited upon tissue damage or infection where they
can differentiate into a range of tissue macrophages and dendritic cells (Ginhoux
and Jung, 2014; Ginhoux et al., 2006). These cells are essential for efficient host
anti-microbial defense (Dunay et al., 2008; Grainger et al., 2013); however,
monocyte mediated inflammation has been implicated in many inflammatory
diseases, including atherosclerosis. Furthermore, monocytes can be recruited to
tumor sites and inhibit tumor-specific immune defense. Finally, eosinophils are
required for host defense against multicellular parasites such as gastrointestinal
helminthes. As with neutrophils and monocytes, eosinophils are closely linked to
certain inflammatory diseases such as allergy, asthma, and obesity (Reese et al.,
2007; Wu et al., 2011). Hypereosinophilic syndrome (HES) is a group of disorders
characterized by eosinophilia and a wide range of clinical manifestations as a
result of eosinophil induced autoinflammation. Of note, the lifespan of eosinophils
from HES patients has been reported to be abnormally increased (Dale et al.,
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1976). Additionally, eosinophils isolated from the blood of patients with asthma
exhibited delayed apoptosis when cultured ex vivo (Kankaanranta et al., 2000). As
such, understanding how the lifespan of these cells is regulated is important for
the development of therapies to augment protective immunity and dampen
immunopathology.
β chain cytokines and short-lived myeloid lifespan
Pathogen and host-derived cues are well known to influence the lifespan of
these short-lived myeloid cells. Of these environmental cues, cytokines that signal
through the common β chain receptor, IL-3, IL-5, and GM-CSF, are known to be
key regulators of the lifespan of short-lived myeloid cells (Hirai et al., 2006). In vivo
administration of either GM-CSF or IL-3 stimulates granulopoiesis, the
hematopoiesis of granulocytes (Metcalf et al., 1986, 1987), as well as
monocytopoiesis, the hematopoiesis of monocytes (Elliott et al., 1989). IL-5 is
more narrow in its impact on bone marrow, and predominately drives the
development of eosinophils (Dent et al., 1990). Similarly, genetic deficiency of the
common β chain receptor, Csf2rb, results in defects in the number of circulating
eosinophils, as well as bone marrow differentiated neutrophil, monocyte, and
eosinophil colonies (Nishinakamura et al., 1995; Robb et al., 1995). In contrast to
humans, mice have an IL-3 specific β chain receptor, and IL-3 dependent
compensation likely contributes to the normal circulating numbers of neutrophils
and monocytes in Csf2rb null mice.
Although these cytokines clearly impact the rate of production of
neutrophils, monocytes, and eosinophils, they also have potent effects on the
14

survival of these immune cells in the periphery. For example, IL-5 maintains the
viability of ex vivo cultured mouse eosinophils (Yamaguchi et al., 1988), GM-CSF
prolongs the survival of human neutrophils by inhibiting programmed cell death
(Brach et al., 1992), and IL-3 promotes the survival of multiple hematopoietic
lineages (Songyang et al., 1997). Variations in the quantity of these cytokines in
circulation can significantly impact the survival of these cells in vivo. For example,
several subtypes of HES have been associated with elevated production of IL-5
(Simon et al., 2010), which is thought to promote eosinophilia in part through the
increased survival these cells (Park and Bochner, 2010). Monoclonal antibody
neutralization of IL-5 may hold promise for subsets of HES patients, as treatment
of eosinophil-infiltrated tissue from allergic rhinitis and asthma patients with antiIL5 was found to induce eosinophil apoptosis and decreased tissue eosinophilia
(Simon et al., 1997). Thus, at a cellular level, short-lived myeloid cells integrate
and translate common β chain and other pro-survival signals into a cellular
lifespan. How at the molecular level these pro-survival cues are transformed into
a particular lifespan is largely unknown.
The pro-apoptotic gene Bcl2l11 (Bim) has been shown to be an important
regulator of myeloid and lymphoid homeostasis (Bouillet et al., 1999; Shinjyo et
al., 2001). BCL2L11 contains a Bcl-2 homology domain 3 (BH3), and can
sequester and inhibit the BCL-2 family members BCL2, BCL-XL, and MCL1 from
performing their pro-survival functions (O’Connor et al., 1998; Wang and Youle,
2009). In particular, in myeloid cells, apoptosis is thought to be a tightly regulated
balance between pro-apoptotic BCL2L11 and anti-apoptotic MCL1. Mice deficient
15

for Bcl2l11, accumulate myeloid cells and have more than a two-fold increase in
granulocytes and monocytes in circulation (Bouillet et al., 1999). Bim has been
described to be both transcriptionally and post-transcriptionally regulated (Ley et
al., 2005). Of note, pro-survival cytokine deprivation is a well-appreciated and
fundamental inducer of Bcl2l11 transcription (Shinjyo et al., 2001). Although
environmental cues, such as common β chain cytokines, are known to impact
short-lived myeloid lifespan, and Bcl2l11-mediated apoptosis is known to control
short-lived myeloid cell death, how these pathways intersect at the molecular level
is largely unknown. Additionally, the extreme short-lived nature of neutrophils,
eosinophils, and “classical” monocytes is highly cell-type specific; thus, how this
regulation is further refined to these specific cell types is unclear.
Genome wide association studies (GWAS) have revealed that most
polymorphisms associated with human disease fall within non-protein coding
sequences such as lncRNAs (Zhang and Lupski, 2015). As discussed above,
lncRNAs are highly cell-type specific in their expression pattern, and have been
described to be dynamically induced in response to extracellular signals such as
vitamin A and temperature (Heo and Sung, 2011; Xing et al., 2014). Nevertheless,
the roles of lncRNAs in the immune system are not well understood, and have not
been studied as regulators of immune homeostasis in response to extracellular
cues. Importantly, given their cell-type specific expression patterns, modulating
lncRNA expression may represent a viable therapeutic strategy for the regulation
of biological processes in specific populations of cells. Thus, understanding the
function of lncRNAs in the regulation of short-lived myeloid cell homeostasis may
16

facilitate the development of targeted therapeutics for either augmenting immunity
or limiting immunopathology.
17
Figures and certain excerpts in Chapter 1 were previously published in Mowel and
Kotzin et al. 2017.(Mowel et al., 2017b)
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Chapter 2 : The long non-coding RNA Morrbid regulates Bim and
short-lived myeloid cell lifespan
ABSTRACT
Neutrophils, eosinophils and “classical” monocytes collectively account for
~70% of human blood leukocytes and are among the shortest-lived cells in the
body. Precise regulation of the lifespan of these myeloid cells is critical to maintain
protective immune responses while minimizing the deleterious consequences of
prolonged inflammation. However, how the lifespan of these cells is strictly
controlled remains largely unknown. Here, we identify a novel long non-coding
RNA (lncRNA) that we termed Morrbid, which tightly controls the survival of
neutrophils, eosinophils and “classical” monocytes in response to pro-survival
cytokines. To control the lifespan of these cells, Morrbid regulates the transcription
of its neighboring pro-apoptotic gene, Bcl2l11 (Bim), by promoting the enrichment
of the PRC2 complex at the Bcl2l11 promoter to maintain this gene in a poised
state. Notably, Morrbid regulates this process in cis, enabling allele-specific control
of Bcl2l11 transcription. Thus, in these highly inflammatory cells, changes in
Morrbid levels provide a locus-specific regulatory mechanism that allows for rapid
control of apoptosis in response to extracellular pro-survival signals. As MORRBID
is present in humans and dysregulated in patients with hypereosinophilic
syndrome, this lncRNA may represent a potential therapeutic target for
inflammatory disorders characterized by aberrant short-lived myeloid cell lifespan.
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RESULTS
Neutrophils, eosinophils and Ly6Chi “classical” monocytes represent a first
line of defense against nearly all pathogens (Ginhoux and Jung, 2014; Manz and
Boettcher, 2014). Yet, these short-lived myeloid cells also contribute to the
development of several inflammatory diseases (Ginhoux and Jung, 2014; Manz
and Boettcher, 2014). Cytokines and metabolites tightly regulate the function and
lifespan of these cells; however, how these cues are translated into an optimal
cellular lifespan is largely unknown. Emerging evidence indicates that certain
lncRNAs can integrate extracellular inputs with chromatin-modification pathways
allowing cells to rapidly adapt to their environment (Heo and Sung, 2011; Xing et
al., 2014). As such, we investigated whether lncRNAs control the function or
lifespan of short-lived myeloid cells in response to extracellular cues. We first
analyzed multiple RNA-seq datasets for lncRNAs preferentially expressed by
mature short-lived myeloid cells (Bouffi et al., 2015; Luo et al., 2015). We identified
an uncharacterized lncRNA (Gm14005) that we termed Morrbid (MyelOid Rna
Regulator of Bim-Induced Death). Morrbid is conserved across species, contains
5 exons, is poly-adenylated, and localized predominately to the nucleus bound to
chromatin (Fig. 2.1a-d).

Importantly, this lncRNA is highly and specifically

expressed by mature eosinophils, neutrophils, and “classical” monocytes in both
mice and humans (Fig. 2.1e-i).
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Figure 2.1. lncRNA Morrbid conservation, localization, and expression
a) Human neutrophil and mouse granulocyte normalized RNA-seq and ChIP-seq tracks
at the Morrbid locus. b) Single molecule Morrbid RNA FISH. c) Conservation of the
Morrbid loci across species visualized using the rankVista display with mouse as the
reference sequence. Green highlights annotated mouse exonic regions and
corresponding regions in other indicated species. d) Cytoplasmic, nuclear, and chromatin
subcellular RNA fractionation of LPS stimulated immortalized BMDMs with qPCR of
indicated target transcripts (average of 4 independent experiments). e) Quantification of
Morrbid FISH spots per indicated cell population. Cells were stained with Morrbid RNA
probes conjugated to 2 different fluorophores, and spots colocalizing in both fluorescent
channels were quantified. f) Mature eosinophil transcriptome sorted in descending order
of log(RPKM) gene expression, with annotated select reported eosinophil-associated
genes. g) Average number of Morrbid RNA copies per cell in sorted neutrophils and B
cells. (Left) Standard curve generated using in vitro transcribed Morrbid RNA spiked into
Morrbid-deficient RNA isolated from spleen. (Right) calculated per cell Morrbid RNA
copies (n=3 replicates from independent mice). h) qPCR expression of mouse (n=3;
representative of 3 independent experiments) and i) human Morrbid in indicated cell-types
and tissues (n=7). Error bars show s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001 (one-way
Anova with Tukey post hoc d; two-sided t-test g). Figure from Kotzin et al. 2016.
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lncRNA Morrbid is a critical regulator of eosinophils, neutrophils and Ly6Chi
monocytes
To investigate the role of Morrbid in vivo, we deleted the Morrbid locus to
generate Morrbid-deficient mice. Strikingly, and in accordance with the expression
profile of Morrbid, we found that eosinophils, neutrophils, and Ly6Chi “classical”
monocytes were drastically reduced in the blood and tissues of these mice (Fig.
2.2a-b). This defect was highly specific to these three cell-types, as well as blood
Ly6Clo monocytes (data not shown), which have been suggested to be progeny
of Ly6Chi monocytes (Yona et al., 2013). All other lymphoid and myeloid cell types
were unaffected (Fig. 2.2a-b, data not shown). Similarly, knockdown of Morrbid in
vivo also led to a specific reduction in the frequency of short-lived myeloid cells in
blood and spleen (data not shown). Finally, as these cells play a critical role in
protective immunity and in the development of immunopathology, we found that
Morrbid-deficent mice were highly susceptible to bacterial (L. monocytogenes)
infection (Fig. 2.2c-d), and protected from eosinophil-driven allergic lung
inflammation (Fig. 2.2e-g). Together, these results support a critical and selective
role for this lncRNA and potentially DNA elements within its locus in short-lived
myeloid cell homeostasis.
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Figure 2.2. Morrbid is a critical regulator of eosinophils, neutrophils and Ly6Chi
monocytes.
a-b) WT and Morrbid-deficient flow-cytometry plots and absolute counts from a) blood and
b) spleen (n=3-5; representative of 7 independent experiments). c-d) L. monocytogenes
infection of WT and Morrbid-deficient mice. c) Survival and weight loss (n=9,
representative of 3 independent experiments). d) CFUs/g from indicated organs (n=5;
representative of 3 independent experiments). e-g) WT and Morrbid-deficient mice
challenged with papain or PBS. e) Absolute numbers of indicated cell populations in lung
tissue and BAL. f) qPCR expression in lung tissue. g) Representative H&E and PAS lung
histology. (n=3-4 mice per group; representative of two independent experiments). Error
bars show s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-sided t-test a,b,d; Mantel-Cox
test c, Mann-Whitney U-test e,f). Figure from Kotzin et al. 2016.
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Morrbid controls eosinophil, neutrophil and Ly6Chi monocyte lifespan
Eosinophils, neutrophils, and Ly6Chi monocytes originate from common
progenitors in the bone marrow (BM)1,8, with extracellular cues driving the
developmental and differentiation programs needed to produce each of these cell
types (Geissmann et al., 2010; Manz and Boettcher, 2014). Using mixed BM
chimeras, we found that Morrbid-deficient BM cells have a significant defect in the
generation of short-lived myeloid cells (data not shown), indicating that Morrbid
acts in a cell-intrinsic manner. We next sought to determine whether Morrbid
regulates short-lived myeloid cell development. Early progenitors of each of these
cell-types express low levels of Morrbid and its expression increases throughout
development to reach maximal levels in fully mature eosinophils, neutrophils, and
Ly6Chi monocytes (Fig. 2.3a-b). In accordance with this pattern of expression,
the progenitors of each of these cell-types were intact in Morrbid-deficient mice
(Fig. 2.3a,c). These results suggest that Morrbid regulates the frequency of mature
eosinophils, neutrophils, and monocytes, but not their progenitors.
Mature populations of myeloid cells are controlled by several mechanisms,
including homeostatic proliferation, trafficking, and cell death. We found no defects
in homeostatic proliferation in Morrbid-deficient mice (Fig. 2.3d). Mature shortlived myeloid cells were substantially reduced in the BM of Morrbid-deficient mice
(Fig. 2.3c). Eosinophils can be differentiated from BM in vitro (Dyer et al., 2008).
Using this in vitro system with Morrbid-deficient BM, we observed a near absence
of eosinophils (Fig. 2.3e), suggesting that Morrbid controls a dominant process
independent

of

cell

trafficking.

Strikingly,
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Morrbid-deficient

eosinophils,

neutrophils, and Ly6Chi monocytes were all highly prone to apoptosis in BM
cultured ex vivo (Fig. 2.3f).

In additional studies, we observed significantly

increased apoptosis in vitro in BM-derived eosinophils, and in vivo during L.
monocytogenes infection in the absence of Morrbid (data not shown). Given the
close relationship between apoptosis and cellular lifespan, we hypothesized that
Morrbid is a regulator of short-lived myeloid cell half-life. Using BrdU to label
circulating neutrophils and determine their decay rate, we observed a ~2-fold
decrease in the half-life of these cells (Fig. 2.3g-h). These results indicate that
Morrbid regulates short-lived myeloid cell lifespan through control of apoptosis.
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Figure 2.3. Morrrbid controls eosinophil, neutrophil and Ly6Chi monocyte lifespan
a) Schematic of short-lived myeloid cell development. b) Morrbid qPCR expression in the indicated
sorted progenitor and mature cells (n=3-5 mice per group; representative of 3 independent
experiments). c) absolute numbers of the indicated cell-types in bone marrow (BM) from WT and
Morrbid-deficient mice (n=3-5; representative of 3 independent experiments). d) Frequency of BrdU
incorporation in the indicated WT and Morrbid-deficient immune cell populations from blood. Mice
were analyzed 24 hours following one dose of 2 mg BrdU (n = 3 mice per group). e) Representative
flow-cytometry plots and absolute counts of mature eosinophils of BM-derived eosinophil culture
on day 12 (D12) in WT and Morrbid-deficient mice (n=3 mice per group, results representative of 3
independent experiments). f) Frequency of Casp+ (Z-VAD-FMK+) in cultured BM cells (n=3 mice;
representative of 2 independent experiments). g) Frequency and absolute number of blood
neutrophils from WT or Morrbid-deficient mice that were pulsed two times with 2 mg BrdU 3 hrs
apart and monitored over 5 days. (n = 4 mice per group; data are representative of 2 independent
experiments). h) Half-life of BrdU pulse-labeled neutrophils in blood in vivo (n=4 mice;
representative of 2 independent experiments). Error bars show s.e.m. *p < 0.05, **p < 0.01, and ***p
< 0.001 (two-sided t-test). Figure from Kotzin et al. 2016.
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Some lncRNAs regulate the expression of neighboring genes (Wang et al.,
2011; Zhang et al., 2014; Wang et al., 2015; Maass et al., 2012). The pro-apoptotic
gene Bcl2l11 (Bim) is located ~150-kb downstream of Morrbid (see Fig. 2.1c).
Bcl2l11 has been shown to be an important regulator of myeloid homeostasis
(Shinjyo et al., 2001; Villunger et al., 2003). Thus, we hypothesized that Morrbid
regulates short-lived myeloid cell lifespan through its control of Bcl2l11 expression.
Indeed, the protein and mRNA levels of Bcl2l11 were dramatically elevated in
eosinophils, neutrophils, and Ly6Chi monocytes from Morrbid-deficient mice (Fig.
2.4a-d). In concordance with the pattern of Morrbid expression, Bcl2l11 was
maximally elevated in the mature state of each of these cell lineages in Morrbiddeficient mice (Fig. 2.4e), and was not dysregulated in other myeloid and lymphoid
cell populations (Fig. 2.4d,f). Importantly, key myeloid lineage transcription factors
and other genes neighboring this lncRNA were largely unaffected in the absence
of Morrbid (data not shown). In summary, these results suggest that Morrbid
represses Bcl2l11 expression in short-lived myeloid cells.
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Figure 2.4. Morrbid regulates neutrophil, eosinophil, and Ly6Chi monocyte
lifespan through control of pro-apoptotic Bcl2l11
a) Bcl2l11 qPCR expression in indicated cell-types sorted from BM (n=3; representative
of 2 independent experiments). b) Western blot analysis of BCL2L11 protein expression
in WT and Morrbid-deficient sorted BM neutrophils. c) BCL2L11 protein expression
measured by flow-cytometry in blood neutrophils from WT, Morrbid-deficient, and Bcl2l11deficient mice (n=1-4 mice per group). d) BCL2L11 protein expression assessed by flowcytometry in indicated BM cell-types. (Left) Representative histograms. (Right) MFI
quantification (n=3-5 mice, representative of 3 independent experiments). e) BCL2L11
protein expression in the indicated progenitors and mature cell-types from WT and
Morrbid-deficient mice. n/a indicates that too few cells were present for MFI quantification
(n=3-5 mice per group, results representative of 3 independent experiments). f) BCL2L11
expression measured in the indicated cell populations from WT and Morrbid-deficient mice
(n=3, results representative of two independent experiments). Error bars show s.e.m. *p <
0.05, **p < 0.01, and ***p < 0.001 (two-sided t-test). Figure from Kotzin et al. 2016.
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To specifically address the role of Morrbid RNA in the regulation of Bcl2l11
expression, we first established an in vitro eosinophil culture system in which we
could study the function of Morrbid RNA in the absence of genetic disruptions (Fig.
2.5a). Using this system, we found that shRNA-mediated knockdown of Morrbid
RNA results in a significant elevation in BCL2L11, which was accompanied by a
substantial decrease in eosinophil survival (Figure 2.5b-d). We observed similar
results using transfection of locked nucleic acids (LNAs) as an independent
knockdown technique (Figure 2.5e). We next sought to corroborate these results
in a different cell-type within the myeloid cell lineage. Interestingly, we found that
lipopolysaccharide (LPS) stimulated BM-derived macrophages (BMDMs) highly
upregulated Morrbid (Figure 2.5f). Notably, LNA knockdown of Morrbid, deletion
of Morrbid’s promoter, or deletion of its locus in LPS stimulated BMDMs resulted
in a striking increase in Bcl2l11 expression and apoptosis (Figure 2.5f-i). Overall,
these results indicate that Morrbid RNA is a critical regulator of Bcl2l11 expression
and short-lived myeloid cell survival.
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Figure 2.5. Morrbid repression of Bcl2l11 and short-lived myeloid apoptosis is
RNA-dependent
a) Schematic of shRNA transduced bone marrow (BM)-derived eosinophil system. b-d) Bone
marrow (BM)-derived eosinophils transduced with control or Morrbid-specific shRNAs. (b) Morrbid
qPCR expression. (c) BCL2L11 protein expression and (d) absolute eosinophil counts (n=3 mice
per group, representative of 2 independent experiments). e) Morrbid and Bcl2l11 expression of WT
BM-derived eosinophils transfected with Morrbid-specific LNA 3 and control locked nucleic acids
(LNAs). (each dot represents the average of 2-3 biological replicates, data pooled from 5
independent experiments). f) Morrbid and Bcl2l11 expression of WT and Morrbid-deficient BMderived macrophages (BMDMs) at the indicated time points following LPS stimulation. Expression
is represented as fold change from time 0 (t0) (n=3 mice per group, representative of 3 independent
experiments). g-h) LPS-stimulated BM-derived macrophages transfected with pooled Morrbidspecific (LNA 1-4) or scrambled (Cntrl LNA) antisense locked nucleic acids (LNAs). g) Morrbid and
Bcl2l11 qPCR expression, and h) Annexin V+ expression (n=3 mice per group, representative of 4
independent experiments). i) Morrbid and Bcl2l11 qPCR expression in bulk Morrbid promoter
targeted immortalized BMDMs. Cells were sorted for GFP and mCherry Cas9-gRNA expressing
plasmids, and stimulated for 6 hours with LPS (n=3 LPS stimulated cultures, average of 3
independent experiments). (two-sided t-test). Error bars show s.e.m. *p < 0.05, **p < 0.01, and ***p
< 0.001 (two-sided t-test). Figure from Kotzin et al. 2016.
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Pro-survival cytokines repress pro-apoptotic Bcl2l11 through induction of Morrbid
RNA
Pro-survival cytokines can potently influence the lifespan of immune cells.
One well-described mechanism of this control is through the repression of Bcl2l11
(Bouillet et al., 1999; Shinjyo et al., 2001). We hypothesized that cytokines from
the common β-chain receptor family (IL-3, IL-5, and GM-CSF), which are known
to promote the survival of eosinophils, neutrophils, and Ly6Chi monocytes,
regulate Bcl2l11 expression through the induction of Morrbid.

To test this

hypothesis, we first withdrew cytokines from cultured BM-derived eosinophils and
quantified Morrbid and Bcl2l11 expression by qPCR. Consistent with our
hypothesis, we noted a marked decrease in Morrbid expression and an increase
in Bc2l11 levels (Fig. 2.6a). Subsequent addition of IL-5, IL-3, or GM-CSF induced
Morrbid expression, which was accompanied by Bcl2l11 repression (Fig. 2.6a).
Similarly, ex-vivo β-chain cytokine stimulation, but not G-CSF stimulation,
significantly induced Morrbid and a corresponding repression of Bcl2l11 in
neutrophils and Ly6Chi monocytes (Fig. 2.6b, data not shown). Importantly,
Morrbid-deficient neutrophils were unable to inhibit Bcl2l11 expression upon
addition of β-chain cytokines (Fig. 2.6c). These results suggest that β-chain
cytokines repress Bcl2l11 expression in short-lived myeloid cells in a Morrbiddependent manner.
Dysregulated immune cell survival is central to many human
hematological and inflammatory diseases. Hypereosinophilic syndrome (HES) is
a group of disorders characterized by eosinophilia and a wide range of clinical
manifestations(Simon et al., 2010). Several HES subtypes have been
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associated with increased production or responsiveness to IL-5(Simon et al.,
2010). We therefore reasoned that eosinophils from HES patients would
overexpress MORRBID, and that IL-5 levels would positively correlate with this
overexpression. We screened patients with varied subtypes of HES (Fig. 2.6d),
and found that eosinophils from these patients expressed significantly higher
levels of MORRBID than that of healthy controls (Fig. 2.6e). Additionally, we
observed that plasma IL-5 levels positively correlated with MORRBID expression
in eosinophils (Fig. 2.6f). These results suggest a potential role for MORRBID in
HES and other inflammatory diseases characterized by high levels of β-chain
cytokines and altered short-lived myeloid cell lifespan.
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Figure 2.6. Pro-survival cytokines repress Bcl2l11 through induction of Morrbid
RNA
a) Morrbid and Bcl2l11 qPCR expression in BM-derived eosinophils following
withdrawal/stimulation with indicated cytokines (n=3 mice, representative of 2 independent
experiments). b-c) Morrbid and Bcl2l11 qPCR expression in b) WT and c) Morrbiddeficient sorted BM cell-types stimulated with indicated cytokines. (n=3-4 mice,
representative of 3 independent experiments). d-f) MORRBID expression in human
hypereosinophilic syndrome (HES). d) Absolute eosinophil count, e) purified eosinophil
MORRBID qPCR expression, and f) correlation between log(plasma IL-5) and MORRBID
expression. (each dot represents one individual; n=2-12 per disease group). Familial HES
(FHES), PDGFRA+ HES (PDGFRA), episodic angioedema and eosinophilia (EAE),
lymphocytic variant HES (LHES), HES of undetermined significance (HEus), and parasitic
infection (PARA). Error bars show s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-sided
t-test a-e, Spearman’s correlation f). Figure from Kotzin et al. 2016.
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Morrbid represses Bcl2l11 in cis by maintaining its bivalent promoter in a poised
state
Genes that require both tight regulation and the ability to be rapidly activated
frequently harbor activating (H3K4me3) and repressive (K3K27me3) histone
marks in their promoters, termed bivalent promoters (Voigt et al., 2013). The
Bcl2l11 gene has been previously described to have a bivalent promoter, which
allows this pro-apoptotic gene to be maintained in a poised state (Paschos et al.,
2012). A number of lncRNAs have been described to repress gene expression by
promoting the enrichment of polycomb repressive complex 2 (PRC2) at target
genes, which in turn catalyzes the deposition of H3K27me3 (Rinn et al., 2007;
Zhao et al., 2008). We therefore hypothesized that Morrbid represses Bcl2l11
expression and prevents short-lived myeloid cell apoptosis by promoting PRC2
enrichment and H3K27me3 deposition at the bivalent promoter of Bcl2l11.
To test this hypothesis, we first performed ChIP-qPCR for total polymerase
II (Pol-II), H3K27me3, and the PRC2 subunit EZH2 in neutrophils from wild-type
and Morrbid-deficient mice. In line with the elevated levels of Bcl2l11 in Morrbiddeficient cells, we found that Pol-II occupancy was significantly increased (Fig.
2.7a), and the levels of H3K27me3 and EZH2 were drastically reduced at the
promoter of Bcl2l11 in the absence of Morrbid (Fig. 2.7b-c). We next asked
whether the induction of Morrbid expression promotes the accumulation of PRC2
at the Bcl2l11 promoter. Using the BMDM system in which Morrbid is induced upon
LPS stimulation, we found that Morrbid levels and EZH2 occupancy at the Bcl2l11
promoter concurrently increase in a Morrbid-dependent manner (data not shown).
Finally, using ChIP-seq and ATAC-seq, we did not detect changes in the activating
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histone marks H3K4me1 and H3K4me3, and only a modest increase in chromatin
accessibility at the Bcl2l11 promoter in the absence of Morrbid (data not shown).
Together, these results indicate that Morrbid represses Bcl2l11 expression in
short-lived myeloid cells by promoting the deposition of H3K27me3 at the bivalent
promoter of Bcl2l11.
LncRNAs have been suggested to promote the recruitment of PRC2 to
target genes through direct lncRNA-PRC2 interactions or through indirect
mechanisms (Csorba et al., 2014; Kaneko et al., 2014; Rinn et al., 2007; Sarma et
al., 2014; Zhang et al., 2014; Zhao et al., 2008). To further understand the
mechanism by which Morrbid promotes PRC2 enrichment at the Bcl2l11 promoter,
we first examined whether Morrbid RNA associates with PRC2. Using a recently
generated EZH2 PAR-CLIP dataset (Kaneko et al., 2014), we found that Morrbid
associates with EZH2 (Fig. 2.7d). To further support this association, we
performed RNA immunoprecipitation against EZH2 in myeloid cells and found that
Morrbid significantly co-immunoprecipitates with this PRC2 subunit (Fig. 2.7e). We
next asked whether Morrbid RNA associates with chromatin regions within the
Bcl2l11 promoter with which PRC2 also associates. We performed chromatin
isolation by RNA purification (ChIRP)-qPCR in LPS-treated BMDMs. Using DNA
probes that specifically and robustly retrieved Morrbid RNA (Fig. 2.7f), we found
that Morrbid association with chromatin was significantly enriched at the Bcl2l11
promoter (Fig. 2.7g). Finally, we asked how Morrbid RNA comes into proximity of
the Bcl2l11 promoter. A number of lncRNA genes have been reported to loop into
proximity with the genes that they regulate(Maass et al., 2012; Ranzani et al.,
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2015; Wang et al., 2011, 2015; Zhang et al., 2014); thus, we reasoned that the
Morrbid and Bcl2l11 loci interact with one another through DNA looping. Using
chromosome conformation capture (3C), we indeed observed a long-distance
association between Bcl2l11 and the Morrbid locus in short-lived myeloid cells
(Fig. 2.7h). Altogether, these results suggest a model in which Morrbid proximity
to Bcl2l11, mediated through DNA looping, enables Morrbid RNA to promote PRC2
enrichment within the Bcl2l11 promoter through direct Morrbid-PRC2 interactions.
These data do not exclude the possibility of Morrbid-dependent PRC2 recruitment
through additional indirect mechanisms.
Our findings suggest an important role for PRC2 in Morrbid-dependent
repression of Bcl2l11. Yet, whether short-lived myeloid cell survival depends on
PRC2-mediated transcriptional repression of Bcl2l11 is not known. We therefore
cultured eosinophils in the presence of a specific inhibitor of EZH2, GSK126. We
observed a dose-dependent increase in BCL2L11 and eosinophil apoptosis upon
PRC2 inhibition (Fig. 2.7i-j).

Importantly, Bcl2l11-deficient eosinophils were

resistant to cell death following abrogation of PRC2 activity (Fig. 2.7j). These
results demonstrate that PRC2 regulates short-lived myeloid cell survival
specifically through repression of Bcl2l11 expression, further supporting a critical
role for Morrbid in the regulation of the lifespan of these highly inflammatory cells.
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Figure 2.7. Morrbid represses Bcl2l11 by maintaining its bivalent promoter in a
poised state
a-c) ChIP-qPCR for a) total Pol-II enrichment, b) H3K27me3, and c) EZH2 within the
Bcl2l11 promoter and gene body in sorted WT and Morrbid-/- neutrophils. Represented as
relative enrichment to the indicated Actb or Myod1 control primer set. Each dot represents
1-2 pooled mice. d) Venn diagram summary of EZH2 PAR-CLIP analysis, with
representation of tags and RNA-protein contact sites (RCSs) as determined by PARalyzer
mapping to Morrbid (GSE49433). e) Co-immunoprecipitation of the PRC2 family member
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EZH2 and Morrbid in 6-12 hour stimulated BM-derived macrophages with IgG or αEZH2
assessed by qPCR. Data are represented as enrichment over IgG control (n=6 biological
replicates pooled from 2 independent experiments, representative of 3 independent
experiments). f) Validation of Morrbid RNA pull-down over other RNAs using pools of
Morrbid or LacZ probes (n=3, average of 3 independent experiments). g) ChIRP-qPCR of
Morrbid RNA occupancy (average of 3 independent experiments). h) 3C of the Bcl2l11
promoter and indicated genomic regions (average of 3 independent experiments). i-j) WT
and Bcl2l11-deficient BM-derived eosinophils treated with the EZH2 inhibitor GSK126. i)
BCL2L11 protein expression on treatment day 5. i) Number of cells relative to DMSO
treatment control (n=3 mice per dose, representative of 2 independent experiments). Error
bars show s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-sided t-test a-g; one-way
Anova with Tukey post hoc i-j). Figure from Kotzin et al. 2016.
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In additional studies, we found that Morrbid-heterozygous mice largely
recapitulated the phenotype of mice lacking both alleles of Morrbid (Fig. 2.8a). In
light of this dominant heterozygous phenotype and the observed Morrbid-Bcl2l11
DNA loop, we hypothesized that Morrbid functions in cis to repress Bcl2l11. As
such, we expected that deletion of Bcl2l11 on the same chromosome as that of the
Morrbid-deficient allele will normalize Bcl2l11 expression in short-lived myeloid
cells and rescue their numbers, but that deletion of Bcl2l11 on the opposite
chromosome would not (Fig. 2.8b). We therefore generated all permutations of
Morrbid and Bcl2l11 double-heterozygous mice (Fig. 2.8c). These results clearly
demonstrated that deletion of Bcl2l11 in cis but not in trans of the Morrbid-deficient
allele normalized Bcl2l11 expression (Fig. 2.8d) and rescued short-lived myeloid
cell numbers (Fig. 2.8e-f). Other cell-types were largely unaltered in these genetic
backgrounds (data not shown). This complete rescue in cis double-heterozygous
mice indicates that Morrbid acts in an allele-specific manner to regulate Bcl2l11
expression and short-lived myeloid cell lifespan.
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Figure 2.8. Morrbid controls Bcl2l11 and short-lived myeloid survival in cis
a) Cell number and b) BCL2L11 protein expression of indicated cell populations from the
blood of WT, Morrbid-heterozygous, and Morrbid-deficient mice (n=3-5 mice per group,
results representative of 3 independent experiments). c-f) Allele-specific combinations of
Morrbid- and Bcl2l11-deficient mice. c) Schema. d) BCL2L11 MFI of indicated cell-types.
e) Representative flow-cytometry of blood eosinophils. f) Absolute counts of indicated
splenic cell-types (n=3-9 mice per group). Error bars show s.e.m. *p < 0.05, **p < 0.01, and
***
p < 0.001 (one-way Anova with Tukey post hoc). Figure from Kotzin et al. 2016.
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DISCUSSION
In these studies, we identified the lncRNA Morrbid and show that this
lncRNA integrates extracellular signals to control the lifespan of eosinophils,
neutrophils, and monocytes through allele-specific suppression of Bcl2l11
expression (Fig. 2.9). As this lncRNA is present in humans and dysregulated in
patients with HES, a better understanding of how Morrbid RNA and potentially
DNA elements within its locus regulate Bcl2l11 may provide new therapeutic
approaches for several human inflammatory diseases. Finally, our results
demonstrate that lncRNAs can function as highly cell-type specific local effectors
of extracellular cues to control immunological processes that require rapid and
strict regulation.

Figure 2.9. Working model of the role of the lncRNA Morrbid in short-lived myeloid cells
Morrbid integrates extracellular signals to control the lifespan of eosinophils, neutrophils, and
“classical” monocytes through the allele-specific regulation of Bcl2l11. Pro-survival cytokines
induce Morrbid, which promotes enrichment of the PRC2 complex within the bivalent Bcl2l11
promoter through direct and potentially indirect mechanisms to maintain this gene in a poised state.
Tight control of the turnover of these short-lived myeloid cells by Morrbid promotes a balance of
host anti-pathogen immunity with host damage from excess inflammation. Figure from Kotzin et al.
2016.
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At homeostasis, we found that Morrbid is highly and specifically expressed
in short-lived myeloid cells, which is likely related to the high degree of
responsiveness of these cells to β-chain cytokines. However, other cell types, such
as dendritic cells are also highly sensitive to the β-chain cytokines IL-3 and GMCSF; yet, at homeostasis dendritic cells express low levels of Morrbid RNA and
their numbers are largely unaffected in Morrbid-deficient mice (data not shown).
This discrepancy suggests a separate unknown cell type-specific degree of the
transcriptional regulation of the Morrbid loci at homeostasis that enhances its
expression in short-lived myeloid cells.
BM-derived macrophages do not express appreciable levels of Morrbid at
baseline; however, following LPS stimulation they markedly upregulate Morrbid
expression (Fig. 2.5f). Moreover, Morrbid-deficient BM-derived macrophages do
not exhibit increased Bcl2l11 expression at baseline, but following LPS stimulation
we observed a dramatic derepression of Bcl2l11 (Fig. 2.5f). In combination, these
results suggest two key points. First, Morrbid can be induced by non-β-chain
cytokine family members in non-short-lived myeloid cells. LPS has long been
appreciated to regulate the lifespan of innate immune cells (Lombardo et al., 2007),
and it is possible that it accomplishes this effect through the regulation of Morrbid
expression. Second, extracellular pro-survival cues may unmask the MorrbidBcl2l11 regulatory axis in additional cell types. BM-derived macrophages do not
overexpress Morrbid under homeostatic conditions; yet, following LPS stimulation
Bcl211 is highly overexpressed and these cells undergo apoptosis. Thus, prosurvival factor stimulation in non-short-lived myeloid cells may unmask Morrbid41

Bcl2l11 dependence, and set a “molecular clock” for the death of these cells as
their survival is now dependent on maintaining Morrbid-dependent repression of
Bcl2l11. Along these lines, it has yet to be determined in what cell types Bcl2l11 is
a “poised” promoter at homeostasis. Thus, it is feasible that pro-survival cues
induce the placement of the activating H3K4me3 mark within the Bcl2l11 promoter
to prime these cells to die, thereby making the survival of these cells subsequently
contingent on Morrbid-dependent placement of the inactivating H3K27me3 mark
within the Bcl2l11 promoter.
As discussed in Chapter 1, lncRNAs have been described to function
through a plethora of mechanisms. They can act through RNA intrinsic function,
transcription across their locus, DNA regulatory elements, or encoded short
bioactive peptides. In short-lived myeloid cells, Morrbid controls cellular lifespan in
an RNA intrinsic manner. Additionally, we found that Morrbid RNA associates with
the PRC2 complex, and that the recruitment of this complex to the Bcl2l11
promoter was dependent on the Morrbid locus. Critically, we also found that PRC2
was required for the survival of eosinophils through the repression of Bcl2l11.
Nevertheless, we do not know whether PRC2 is recruited directly or indirectly by
Morrbid to promote short-lived myeloid survival.
Mammalian PRC2 binds thousands of RNAs; yet, no RNA binding motifs
have been identified in PRC2 and no well-validated PRC2 binding motifs have
been identified in RNAs (reviewed in (Davidovich and Cech, 2015)). Moreover,
PRC2 was found to bind HOTAIR and Xist, lncRNAs that pioneered the concept
of lncRNA mediated PRC2 recruitment, with the same affinity as irrelevant
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bacterial mRNAs (Davidovich et al., 2015). Of note, this “promiscuity” of PRC2
binding to RNA does not equate to a lack of specificity, as its target RNA motifs
may be short and present in many RNA species. These findings imply an additional
degree of complexity to Morrbid and other lncRNA mediated recruitment of
chromatin modifying enzymes such as PRC2.
For example, PRC2 has been proposed to scan active transcription through
its promiscuous association with RNA to efficiently target all active loci, and to only
deposit its repressive H3K27me3 mark on chromatin “primed” for repression
(Davidovich and Cech, 2015). The PRC1 dependent chromatin mark, H2AK119ub,
was previously found to promote PRC2 activity, and may play a role in this
chromatin priming (Blackledge et al., 2014). In regards to this model, we do not
know whether PRC1 impacts short-lived myeloid survival, and if Morrbid-deficiency
impacts PRC1 recruitment and H2AK119ub deposition at the Bcl2l11 promoter.
Restriction enzymes bind noncognate sites with high affinity, yet they only
efficiently cleave their target sequences (Loenen et al., 2014). PRC2 may similarly
scan many RNA species through promiscuous binding, but it may only be
enzymatically active in the presence of modifying factors such as RNAs with
specific motifs, or even RNA binding proteins brought into PRC2 proximity through
their mutual RNA binding. Of note, a recent study found that enhancer RNA binding
had the capacity to stimulate CBP histone acetylation (Bose et al., 2017),
demonstrating the concept that noncoding RNA binding can influence the
enzymatic activity of certain proteins. Future studies will need to better
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characterize the affinity of Morrbid RNA for PRC2, and determine whether Morrbid
RNA and other lncRNAs can alter the enzymatic activity of PRC2.
Given the ability of Morrbid to promote Bcl2l11 repression and cell survival,
we predict that this pro-survival mechanism may be co-opted by certain
malignancies. For example, acute myeloid leukemia (AML) cells are known to
have altered cellular lifespan and have been reported to be highly sensitive to
Bcl2l11 upregulation (Zhang et al., 2008). Possibly related to these observations,
FLT3 and TET2 mutations demonstrate cooperativeity in human AML and
contribute to a poor prognosis (Patel et al., 2012). When examining previously
published transcriptional analysis of a mouse model of Tet2-/- Flt3ITD AML, we
found that Morrbid is one of the most highly overexpressed genes in this context
(Shih et al., 2015). Whether these results reflect altered levels or responsiveness
to extracellular pro-survival signals, such as β-chain cytokines, or downstream
dysregulation of Morrbid expression, they suggest that Morrbid may represent a
therapeutic target to enhance Bcl2l11 expression and apoptosis in AML. In further
support of the role of Morrbid in malignancy, recent work has found that human
MORRBID is significantly overexpressed in liver, lung, and breast cancer tumor
tissue (Nötzold et al., 2017).
Whether Morrbid expression in these malignant non-short-lived myeloid
cells also impacts Bcl2l11 expression has yet to be determined. It is important to
note that the same protein factors can have disparate functions in different cell
types. For example, transcription factors expressed in multiple cell lineages can
have highly dissimilar DNA binding patterns and control unique processes in each
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lineage (Arvey et al., 2012). Similarly, although teleologically Bcl2l11 and lifespan
are central to malignancy and Morrbid is overexpressed in many different types of
malignant tissues, Morrbid may still perform distinct functions in these different cell
types.
In summary, here we have identified a lncRNA that we termed
Morrbid that controls the lifespan of eosinophils, neutrophils, and “classical”
monocytes in response to extracellular pro-survival cues. We found that Morrbid
regulates the lifespan of these cells through its recruitment of PRC2 and repression
of Bcl2l11 in cis. This lncRNA is present in humans and overexpressed HES,
suggesting that it may represent a potential therapeutic target in disorders of
dysregulated myeloid lifespan. Moreover, Morrbid may represent a model for how
immune cell types utilize extracellular responsive lncRNAs to fine-tune
fundamental biological processes.

Figures and certain excerpts in Chapter 2 were previously published in Kotzin et al.
2016.(Kotzin et al., 2016)
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Chapter 3 : The lncRNA Morrbid regulates CD8 T cell
homeostasis
ABSTRACT
To combat infections, pathogen-specific CD8 T cells expand dramatically
and develop highly potent effector functions in response to TCR and cytokine
receptor signaling. The expansion and effector function of these cells are tightly
regulated to allow for an effective response to pathogens, while restraining
potential excess inflammation and autoimmunity. Extracellular cues, their
downstream signaling pathways, and transcription factors are all well-known
contributors to the activation and differentiation of CD8 T cells. Long non-coding
RNAs (lncRNAs) have recently emerged as another key regulatory layer in the
immune system; yet, their role in CD8 T cell function is largely unexplored. Here
we find that the lncRNA Morrbid is induced and enriched in the cytoplasm of CD8
T cells following viral infection and in response to TCR and type I IFN stimulation.
The Morrbid locus restrains CD8 T cell expansion and contraction following viral
infection, and stimulated Morrbid-deficient CD8 T cells exhibit a hyperactive
effector profile in a cell-intrinsic manner. While the molecular mechanism by which
Morrbid regulates CD8 T cell function is still under investigation, the results
presented here demonstrate that the Morrbid locus, and likely other extracellular
cue-responsive lncRNAs, are critical in finely tuning the protective and pathogenic
potential of cytotoxic CD8 T cells.
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RESULTS
CD8 T cells are a key component of the adaptive immune system and are
essential for host defense against many different pathogens. In response to
infection, pathogen-specific CD8 T cells dramatically expand and gain effector
functions in response to T cell receptor (TCR) stimulation and cytokine signaling
(Zhang and Bevan, 2011). Although these expanded CD8 T cells are highly
specific in their recognition of infected cells through TCR peptide-class I MHC
interactions, their potent effector function has the capacity to damage bystander
host tissue. Thus, as with short-lived myeloid cells, the lifespan and effector
potential of activated CD8 T cells is highly regulated (Kaech and Cui, 2012).
Following pathogen clearance, the majority of responding CD8 T cells undergo
apoptosis with the exception of a small population of long-lived antigen-specific
memory cells (Kaech and Cui, 2012). Extracellular cues, their downstream
signaling pathways, and transcription factors are all well-known contributors to this
regulation of effector function and cell numbers (Joshi et al., 2007; Wiesel et al.,
2012). LncRNAs have recently been described to function as key regulators of
immune responses; we therefore undertook studies to delineate the role of
lncRNAs in CD8 T cell function.
In the work described above, we recently identified a novel lncRNA, termed
Morrbid, that regulates the lifespan of short-lived myeloid cells in response to
extracellular pro-survival cues through the repression of Bcl2l11 (Kotzin et al.,
2016). Bcl2l11 (Bim), is a fundamental regulator of the contraction of effector CD8
T cells (Hildeman et al., 2002). Given the tight regulation of CD8 T cell responses
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by their extracellular environment, the importance of Bcl2l11 in CD8 T cell
contraction, and the critical nature of the Morrbid-Bcl2l11 axis in short-lived
myeloid cells, we hypothesized that Morrbid also regulates CD8 T cell survival and
effector function during an anti-pathogen response.
lncRNA Morrbid is induced in CD8 T cells during viral infection and in response to
TCR and type I IFN stimulation
We first investigated whether Morrbid is expressed in CD8 T cells during
viral infection. Using an existing microarray dataset of gp33-tetramer specific CD8
T cells during acute LCMV Armstrong (Arm) infection, we found that Morrbid was
induced by approximately 6 fold at day 6 post infection relative to naïve controls.
Levels returned to near baseline following this time point (Fig. 3.1a; dataset from
(Doering et al., 2012)). As replicating virus is known to be cleared by day 8 of this
acute strain of LCMV infection (Wherry et al., 2003), the kinetics of Morrbid
expression suggest that Morrbid may be induced downstream of CD8 T cell
activation. T cells are activated in the context of several signals including TCR,
surface co-stimulatory receptors such as CD28, and the inflammatory cytokine
environment (Curtsinger et al., 2003). To better understand what signals drive
Morrbid expression, we first sorted splenic CD8 T cells and activated these cells
in vitro using variable doses of plate bound αCD3/αCD28 or phorbol 12-myristate
13-acetate (PMA)/Ionomcyin (I), a pharmacological surrogate for strong TCR
signaling (Fig. 3.1b). The results showed that high-dose αCD3/αCD28 or PMA/I
significantly induced Morrbid expression relative to unstimulated control cells (Fig.
3.1b). Importantly, induction of Morrbid was only present at non-physiologic high
48

doses of αCD3 or PMA/I stimulation, which suggests that additional signals are
likely important for Morrbid induction in vivo.
Since we previously found that pro-survival cytokines induce Morrbid
expression in short-lived myeloid cells, we reasoned that extracellular cues known
to regulate CD8 T cells might act as signals to drive Morrbid expression during
infection. As such, we provided TCR and CD28 co-stimulation in the context of a
panel of inflammatory cytokines known to be important for CD8 T cell activation.
Using a lower dose of αCD3/αCD28 that alone did not induce Morrbid expression
(Fig. 3.1b), we observed a strong induction of Morrbid with the addition of either
interferon (IFN)-α or IFN-β (Fig. 3.1c). Importantly, IFN-β stimulation alone without
TCR stimulation did not induce Morrbid expression (data not shown). Consistent
with these findings, in a published microarray dataset we found that Morrbid
expression is reduced by nearly 3 fold following LCMV infection in IFNAR-deficient
LCMV-specific CD8 T cells relative to their LCMV-specific wild-type counterparts
(Fig. 3.1d; dataset from (Crouse et al., 2014)). These results therefore show that
Morrbid expression is induced in CD8 T cells after LCMV infection in vivo and in
response to TCR stimulation and type I interferons in vitro.
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Figure 3.1. Morrbid is induced in CD8 T cells during viral infection and in response
to TCR and type I IFN stimulation.
a) Morrbid expression in gp33+ CD8 T cells after LCMV Armstrong infection relative to
naïve (n=3-4 biological replicates). b) qPCR expression of Morrbid in sorted CD8 T cells
from naïve WT spleens stimulated for 4 hrs with the indicated doses of plate-bound αCD3
and 1 μg/mL soluble αCD28, or PMA/I (n = 3 biological replicates). c) qPCR expression
of Morrbid in sorted CD8 T cells from naïve WT spleens stimulated for 48 hrs with 1 μg/mL
plate-bound αCD3, 1 μg/mL soluble αCD28 and 50 ng/mL of the indicated cytokine (n = 3
biological replicates). d) Morrbid expression in WT or IFNAR1-/- P14 gp33+ CD8 T cells
after LCMV infection relative to naïve (n=3 biological replicates) . Error bars show s.e.m.
*P<0.05, **P<0.01, ***P<0.001 (one-way ANOVA with Tukey post-hoc a,b,c; two-sided ttest d)
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Morrbid is a negative regulator of CD8 T cell numbers following viral infection
At homeostasis, Morrbid was expressed at low levels in CD8 T cells, in both
the thymus and in the periphery (Fig. 3.2a). Furthermore, mice deficient for the
Morrbid locus did not demonstrate defects in thymic development or circulating
peripheral CD8 T cell numbers (data not shown, Fig. 3.2b). As such, we next
interrogated whether the Morrbid locus impacts CD8 T cell function following
LCMV infection. First, we independently transferred 20 x 106 wild-type (WT) or
Morrbid-/- splenocytes into congenic (CD45.1+) WT hosts, infected these mice with
LCMV Arm, and assessed CD8 T cell frequency over the course of infection in
blood (Fig. 3.2c). Although the same number of WT and Morrbid-/- CD8 T cells
were initially transferred prior to infection, the Morrbid-/- bulk CD8 T cell population
expanded to greater numbers, and maintained increased numbers following the
acute phase of this infection (Fig. 3.2c). To control for any differences in the TCR
repertoires between WT and Morrbid-/- CD8 T cell populations, as well as to
assess the antigen specific response to LCMV, we generated Morrbid-/- P14 mice,
which express a transgenic TCR specific for the gp33 epitope of LCMV (Butz and
Bevan, 1998). We subsequently adoptively transferred a 1:1 mix of congenic P14
CD8 T cells from wild-type (CD45.1+CD45.2+) and Morrbid-deficient (CD45.2+)
mice into wild-type (CD45.1+) hosts, and assessed CD8 T cell frequency and
number in blood over time following acute LCMV Arm or chronic LCMV Clone 13
(Cl13) infection (Fig. 3.2d). Again, we observed a greater number and frequency
of Morrbid-deficient CD8 T cells compared to WT CD8 T cells at all time points
analyzed (Fig. 3.2d), suggesting that the Morrbid locus impacts both the expansion
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and contraction of CD8 T cells after Armstrong and Clone 13 infection, even when
these cells are exposed to the same antigen and cytokine environment.
Preliminary data from WT P14 and Morrbid-/- P14 CD8 T cells transferred into
independent congenic WT suggests that Morrbid-/- CD8 T cells may have a
functional impact on viral burden during infection and expedite the clearance of
LCMV Arm (data not shown).
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Figure 3.2. Morrbid is a negative regulator of CD8 T cell numbers following LCMV
infection.
a) qPCR expression of Morrbid in sorted double-negative (DN), double-positive (DP),
single-positive (sp) spCD4, and spCD8 from WT thymus and CD4 and CD8 T cells from
WT spleen (n=3 biological replicates). b) Number of splenic CD4 and CD8 T cells from
WT and Morrbid-/- mice (n=4 mice per group, representative 3 independent experiments).
c) Frequency of total donor CD8 T cells over time in mice that received 10 x 106 WT or
Morrbid-/- splenocytes followed by infection with LCMV Armstrong (Arm) (n=5 biological
replicates). d-e) Number and frequency of donor P14 cells was assessed in peripheral
blood over time in mice that received a 1:1 mix of 250 WT (CD45.1+, CD45.2+) and 250
Morrbid-/- (CD45.2+) P14 CD8 T cells followed by d) LCMV Arm or e) LCMV Clone 13
(Cl13) infection. (n = 5 biological replicates, representative of 3 indep exps.). Error bars
show s.e.m. *P<0.05, **P<0.01, ***P<0.001 (two-sided t-test b,c; paired two-sided t-test
d,e).
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CD8 T cell numbers following infection can be influenced by proliferation,
cell death, and trafficking. We observed an increase in the frequency and numbers
of Morrbid-/- CD8 T cells following LCMV infection in all the tissues that we
examined, including blood, spleen, liver, and lung (data not shown), suggesting
that trafficking was likely not responsible for the increase in circulating CD8 T cells.
To determine the contribution of proliferation, we first stimulated WT and Morrbid/- CD8 T cells in vitro using αCD3/αCD28 and IL-2 and assayed their proliferation
by dilution of CFSE (Quah et al., 2007). We observed a minor but significant
increase in the proliferation index and division index of Morrbid-/- CD8 T cells (Fig.
3.3a-c). Co-transferred congenically marked Morrbid-/- P14 CD8 T cells did not
demonstrate a competitive advantage over their WT counterparts until
approximately 5 days post LCMV infection (Fig. 3.3d), a time point after which
responding CD8 T cells have completely diluted cytoplasmic dyes such as CFSE
(Odorizzi et al., 2015). To examine T cell proliferation at these later stages, we
pulsed the mice with the thymidine analog bromodeoxyuridine (BrdU), and
assessed its incorporat11/2/2017 4:11:00 PMion as well as Ki67, a surrogate of
cell cycle entry, 12 hours following BrdU injection. BrdU incorporation and Ki67
frequency were similar between co-transferred WT and Morrbid-/- P14 CD8 T cells
at day 4 and 5 post infection (Fig. 3.3e-f, data not shown), suggesting that the
competitive advantage of Morrbid-/- CD8 T cells is not likely dependent on
increased proliferation. Studies assessing cell death using staining for cell viability,
active caspases, and annexin V, are still ongoing.
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Figure 3.3. Proliferation of Morrbid-deficient CD8 T cells following stimulation in
vitro and in vivo.
a-c) Cell divisions of CFSE-labeled WT and Morrbid-/- CD8 T cells following αCD3,
αCD28, and IL-2 stimulation for 70 hrs. a) Representative flow plot, b) frequency of cells
within each division, and c) division index of each genotype (n=3 mice per group,
representative of 2 independent experiments). d) Ratio of co-transferred Morrbid-/- to WT
P14 CD8 T cells in spleen at the indicated timepoints following LCMV Cl13 infection (n=5
mice per group, representative of 2 independent experiments). e) Representative flow
cytometry and f) frequencies of BrdU incorporation in co-transferred Morrbid-/- and WT
P14 CD8 T cells in spleen at the indicated timepoints following LCMV Cl13 infection. BrdU
was injected 12 hours prior to takedown. (n=5 mice per group). Error bars show s.e.m.
*P<0.05, **P<0.01, ***P<0.001 (two-sided t-test c; paired two-sided t-test d,f).
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Morrbid controls CD8 T cell effector function and naïve cell homeostasis in a cellintrinsic manner
In addition to expanding their numbers, CD8 T cells must also develop
appropriate effector functions, such as cytokine production and degranulation, to
mount efficient anti-pathogen responses (Harty et al., 2000). Thus, we asked
whether Morrbid impacts CD8 T cell effector function. To establish the baseline
effector profile of Morrbid-/- relative to WT CD8 T cells, we activated these cells in
vitro and compared cytokine production and degranulation by flow cytometry. We
observed a significant increase in the frequency of IFN-γ producing Morrbiddeficient CD8 T cells as compared to WT CD8 T cells (Fig. 3.4a,b). In addition, we
observed a significant increase in the cellular quantity of IFN-γ and TNF-α
produced by Morrbid-deficient CD8 T cells, as assessed by mean florescent
intensity (MFI) (Fig. 3.4a,c). Of note, we did not observe differences in the
frequency or intensity of CD107a, a surrogate for degranulation (data not shown,
Fig. 3.4c). These results indicated that in addition to cellular expansion, the
Morrbid locus also restrains CD8 T cell IFN-γ production and other effector
functions following stimulation.
Given the increased numbers and augmented effector profile of Morrbid-/CD8 T cells following stimulation, we next investigated whether this hyperactivity
impacts Morrbid-/- CD8 T cell maintenance of naïve phenotype cells at
homeostasis in vivo. Loss of negative regulators of T cell activation such as
tuberous sclerosis component 2 (Tsc1), a negative regulator of mammalian target
of rapamycin (mTOR), can result in expansion of memory-like CD44hi CD8 T cells
(Yang et al., 2011). In Morrbid-deficient mice we observed a decrease in naïve
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(CD62L+, CD44lo) CD8 T cells with a concordant increase in the effector memory
(CD62L-, CD44hi) compartment (Fig. 3.4d). Thus, Morrbid is important for
maintaining the CD8 T cell naïve population at homeostasis. The expansion of a
memory-phenotype CD8 T cell population in Morrbid-deficient mice potentially
contributed to the rapid responsiveness and hyperactivity exhibited by these cells
following stimulation in vitro or in vivo that we previously observed. To determine
whether the hyperactive effector profile of Morrbid-/- CD8 T cells is also contained
within the remaining naïve CD8 compartment, we sorted naïve (CD62L+, CD44lo)
WT and Morrbid-/- CD8 T cells and differentiated these cells into effector-like cells
in vitro. Differentiated naïve Morrbid-/- CD8 T cells produced more IFN-γ, TNF-α,
and granzyme B than their differentiated naïve WT counterparts (Fig 3.4f, data not
shown), demonstrating that Morrbid-/- hyper-responsiveness stems in part from
the naïve CD8 compartment.
Given the absence of short-lived myeloid cells in Morrbid-deficient animals,
we questioned whether the hyperactivity of Morrbid-deficient CD8 T cells occurs in
a cell-intrinsic or -extrinsic manner. Although our adoptive transfer studies suggest
that the phenotype is cell-intrinsic, we sought to determine whether development
in the absence of a full myeloid compartment contributes to Morrbid-deficient CD8
T cell hyperactivity. First, we transferred WT splenocytes into WT and Morrbid-/hosts to assess the cell-extrinsic impact of host Morrbid-deficiency on CD8 T cell
homeostasis. After 8 weeks, we did not observe any difference in IFN-γ production
or the memory phenotype of WT cells exposed to either a WT or Morrbid-deficient
environment (data not shown). To more rigorously address this questions, we
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generated competitive bone marrow chimeras using sorted LSK cells from WT and
Morrbid-deficient bone marrow mixed 1:1 and transferred into irradiated WT hosts.
After allowing the bone marrow to reconstitute for 9 weeks, we observed a greater
frequency of IFN-γ+ Morrbid-deficient CD8 T cells in response to PMA/I stimulation
as compared to wild-type CD8 T cells, suggesting that increased production of
IFN-γ with Morrbid-deficiency occurs in a cell-intrinsic manner in the absence of
the Morrbid locus (Fig. 3.4h). In addition, we observed a similar loss of naïve
(CD62L+, CD44lo) and expansion of effector memory (CD62L-, CD44hi) CD8 T cells
in the Morrbid-deficient populations as comparted to WT CD8 T cells in the same
recipient hosts. Together, our findings suggest that the Morrbid locus functions in
a cell-intrinsic manner to restrain effector memory phenotype CD8 T cells at steady
state, and to control effector cytokine production following CD8 T cell activation
(Fig. 3.4i). Thus, our data indicate that these alterations are independent of the
defects in the myeloid compartment of Morrbid-deficient mice.
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Figure 3.4 Morrbid controls CD8 T cell effector function and naïve homeostasis in a
cell-intrinsic manner
a) Representative flow cytometry, b) frequencies, and c) mean florescent intensity (MFI)
of indicated proteins in PMA/I stimulated peripheral blood WT and Morrbid-/- CD8 T cells
(n=3 mice per group, representative of 5 independent experiments). d) Representative
flow cytometry and e) frequencies of naïve (NV; CD62L+, CD44lo), central memory (CM;
CD62L+, CD44hi), and effector memory (EM; CD62L-, CD44hi) WT and Morrbid-/- CD8 T
cells from peripheral blood (n = 5 mice per group, representative of 5 independent
experiments). f-g) Frequency and MFI of f) IFN-γ and g) TNF-α production in effector WT
and Morrbid-/- CD8 T cells differentiated in vitro using αCD3, αCD28, and IL-2 with varying
doses of IFNβ (n=3 mice per group, representative of 2 independent experiments). h-i)
Competitive bone marrow chimera mice generated from sorted WT and Morrbid-/- bone
marrow LSK cells transferred into lethally irradiated hosts. h) Frequency of IFN-γ
production and i) NV, CM, and EM memory compartments were assessed at 9 week
following reconstitution and represented as the WT to Morrbid-/- ratio (n = 9 mice pooled
from 2 independent experiments). Error bars show s.e.m. *P<0.05, **P<0.01, ***P<0.001
(two-sided t-test a-g; paired two-sided t-test h-i).
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Bcl2l11 expression is decreased in stimulated Morrbid locus-deficient CD8 T cells,
but may not contribute to their increased expansion and effector function
As previously discussed, Bcl2l11, the key downstream target of Morrbid in
short-lived myeloid cells, is required for appropriate contraction of WT CD8 T cells
following viral clearance (Hildeman et al., 2002). CD8 T cells deficient for Bcl2l11
fail to contract at later stages of infection (Grayson et al., 2006; Hildeman et al.,
2002; Wojciechowski et al., 2006), which closely mirrors the kinetics of Morrbiddeficient CD8 T cells in the later stages of LCMV infection. However, no published
studies have demonstrated whether Bcl2l11 impacts CD8 T cell expansion or
effector function. To better understand if Morrbid-mediated control of Bcl2l11 could
impact CD8 T cell expansion and effector function, we first asked whether Bcl2l11
expression was altered. At homeostasis, Bcl2l11 expression was not altered in
naïve (CD62L+, CD44lo) CD8 T cells of Morrbid-deficient mice at the transcript or
protein levels (Fig. 3.5a-b). Furthermore, and in surprising contrast to short-lived
myeloid cells, Bcl2l11 RNA and protein expression were decreased in Morrbid-/compared to WT CD8 T cells following stimulation in vitro, measured by qPCR and
flow cytometry respectively (Fig. 3.5a-b), as well as at early time points following
LCMV infection in vivo by flow cytometry (Fig. 3.5c-d). As such, we next asked
whether this decrease in Bcl2l11 expression could account for aspects of the
Morrbid-/- CD8 T cell hyperactivity. Our preliminary data suggests that Morrbid-/CD8 T cells produced significantly more IFN-γ than Bcl2l11-/- CD8 T cells (data
not shown). These data demonstrate that the Morrbid locus promotes Bcl2l11
expression following CD8 T cell activation, and that the decreased contraction of
Morrbid-/- CD8 T cells may be mediated by a decrease in Bcl2l11 expression.
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Nevertheless, our findings also suggest that the Morrbid-/- rapid effector profile
likely occurs in a Bcl2l11-independent manner. Work is underway to disentangle
the contribution of decreased Bcl2l11 expression to the enhanced expansion and
effector function of Morrbid-deficient CD8 T cells.

Figure 3.5. Bcl2l11 expression is decreased in stimulated Morrbid locusdeficient CD8 T cells.
a) qPCR of Bcl2l11 expression in sorted naïve (CD62L+CD44lo) WT and Morrbid-/- CD8 T
cells unstimulated or stimulated with αCD3/αCD28 for 24 hours (n=3 mice per group,
representative of 3 independent experiments). b) MFI of BCL2L11 expression in WT and
Morrbid-/- CD8 T cells unstimulated or stimulated with PMA/I for 4 hours (n=3 mice per
group, representative of 3 independent experiments). c-d) MFI of BCL2L11 expression in
co-transferred WT and Morrbid-/- P14 CD8 T cells infected following c) LCMV Arm or d)
LCMV Cl13 infection (n=5 mice per group, representative of 2 independent experiments).
Error bars show s.e.m. *P<0.05, **P<0.01, ***P<0.001 (two-sided t-test a-b; paired twosided t-test c-d).
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Morrbid does not impact the canonical type I IFN response in CD8 T cells
Type I IFNs are well recognized for their potent effects on CD8 T cell
activation, proliferation, differentiation, and survival (Crouse et al., 2015). Although
the functional consequences of type I IFNs can be diverse depending on the
relative timing of IFN exposure and TCR stimulation, within the LCMV system, type
I IFNs have been reported to act directly on CD8 T cells to promote their survival
and effector function (Kolumam et al., 2005; Nguyen et al., 2002; Wiesel et al.,
2012). Given that Morrbid-deficient CD8 T cells exhibit increased survival and
effector function, and CD8 T cell Morrbid expression following LCMV infection is
largely dependent on type I IFN signaling, we reasoned that Morrbid might function
as a negative regulator of type I IFN signaling. In CD8 T cells, canonical type I IFN
signaling is sensed by IFN-alpha/beta receptor (IFNAR) and is relayed through the
downstream phosphorylation of several signal transducer and activator of
transcription (STAT) proteins. Of note, we did not observe any differences in the
surface expression levels of IFNAR1 between naïve WT and Morrbid-/- CD8 T cells
(data not shown). In CD8 T cells, activation of STAT1 is thought to have antiproliferative and pro-apoptotic properties, whereas phosphorylation of STAT4
drives survival, expansion, and effector function (Crouse et al., 2015). To examine
this canonical type I IFN signaling, we first assayed the levels of phosphorylation
of STAT1 and STAT4 in WT and Morrbid-/- CD8 T cells in response to varying
doses of IFN-β in combination with αCD3. WT and Morrbid-/- CD8 T cells were
similarly sensitive to IFN treatment, with a minor reduction in Morrbid-/- STAT1 and
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STAT4 phosphorylation (Fig. 3.6a-c). These results suggest that canonical type I
interferon signaling is not grossly dysregulated in Morrbid-/- CD8 T cells.
To identify other potential downstream targets of Morrbid, we performed
RNA sequencing of sorted naïve wild-type and Morrbid-deficient splenic CD8 T
cells stimulated with αCD3/αCD28 with and without IFN-β. We first asked whether
there were changes in neighboring genes, by comparing expression of genes
within 2 megabases (Mbs) of the Morrbid locus (Fig. 3.6d). Apart from Bcl2l11, we
observed no significant differences in cis gene expression between WT and
Morrbid-deficient CD8 T cells under any stimulation condition. Using a previously
published dataset of Bcl2l11-/- CD8 T cells 6 days following L. Monocytogenes
infection, we generated a gene-set of genes significantly upregulated in the
absence of Bcl2l11 (dataset from (Knell et al., 2013)). Using gene set enrichment
analysis (GSEA), we found that these genes were not significantly enriched in
Morrbid-/- CD8 T cells and were actually enriched in the WT compartment (Fig.
3.6e). These results suggest that Bcl2l11 might be increased in Morrbid-/- CD8 T
cells. Given that we have never observed increased Bcl2l11 expression early
following activation in Morrbid-deficient CD8 T cells, these GSEA data instead
suggest that Morrbid likely functions in a Bcl2l11-independent manner. As Bcl2l11
was the only significantly altered gene within 2 Mbs of the Morrbid locus, these
data also suggest that Morrbid may be functioning in trans.
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Figure 3.6. Morrbid does not impact canonical type I IFN response in CD8 T cells.
a-c) Geometric mean florescent intensity (gMFI) of indicated targets in sorted naïve
(CD62L+CD44lo) WT and Morrbid-/- CD8 T cells stimulated for 1 hour with αCD3/αCD28
and the indicated concentration of IFN-β (n=3 mice per group). a) STAT1 T701
phosphorylation (pSTAT1), b) the ratio of pSTAT1 gMFI to total STAT1 gMFI, and c)
STAT4 Y694 phosphorylation are shown. d) Expression of genes within 1 megabase (Mb)
of the Morrbid locus in sorted naïve (CD62L+CD44lo) WT and Morrbid-/- CD8 T cells left
unstimulated or treated with αCD3/αCD28 or αCD3/αCD28/IFN-β for 6 hours as
determined by RNA sequencing. Reads were STAR aligned and normalized using
DESeq2 (n=3-4 biological replicates per genotype per condition). e) Gene set enrichment
analysis (GSEA) of WT and Morrbid-/- CD8 T cells under the indicated stimulation
conditions using the top 100 most significantly up-regulated genes in Bc2l11-/- OTI CD8
T cells responding to LM-ova (GSE41978). Error bars show s.e.m. *P<0.05, **P<0.01,
***P<0.001 (two-sided t-test a-c; FDR d-e).
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AKT-mTOR dysregulation in the absence of Morrbid impacts CD8 T cell activity
and expansion
Taking an unbiased approach, we used GSEA to determine what pathways
were altered in CD8 T cells in the absence of Morrbid, and found that the PI3KAKT-mTOR pathway was highly dysregulated (Fig. 3.7a). This pathway was
enriched in the WT CD8 T cell compartment under unstimulated conditions. In
contrast, it was enriched in the Morrbid-/- CD8 T cell compartment following
stimulation with αCD3/αCD28 and IFN-β, but not with αCD3/αCD28 alone,
paralleling the conditions needed to induce Morrbid expression (see above Fig.
3.1c). It has recently been appreciated that AKT is a key downstream mediator of
IFN signaling, including IFN stimulated autophagy, glucose uptake, and translation
of interferon stimulated genes (ISGs) (Burke et al., 2014; Kaur et al., 2008; Saleiro
et al., 2015). In particular, AKT has been reported to be proximally phosphorylated
following type I IFN signaling (Rani et al., 2002); thus, we hypothesized that altered
AKT activity might help drive the hyperactive phenotype that we observe with
Morrbid deficiency. As such, we first asked whether the phosphorylation of AKT
might be altered following TCR and IFN stimulation of WT and Morrbid-/- CD8 T
cells. Under these conditions, we observed more rapid phosphorylation of AKT at
S473 in Morrbid-/- CD8 T cells (Fig. 3.7b-c). AKT is a fundamental signaling hub
downstream of TCR engagement with costimulation (Smith-Garvin et al., 2009).
To determine if altered AKT activity represented a specific defect, or was
representative of global dysregulation of TCR signaling, we assayed other
pathways downstream of the TCR stimulation. Of note, we did not observe gross
alterations in global tyrosine phosphorylation, or other key proximal TCR signaling
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pathways such as calcium flux and Erk phosphorylation (data not shown, Fig.
3.7d-f).
AKT and its downstream targets are fundamental regulators of CD8 T cell
differentiation, growth, function, and survival (Smith-Garvin et al., 2009). mTOR, a
core kinase component of mTOR complex 1 (mTORC1) and mTORC2, is activated
downstream of AKT and mediates many of the functions attributed to AKT
activation in CD8 T cells (Buck et al., 2015). Additionally, as discussed above,
hyperactivity of mTOR can lead to loss of CD8 T cell quiescence (Yang et al.,
2011). First, to better understand the influence of this canonical AKT signaling
pathway on Morrbid-/- effector function, we treated WT and Morrbid-/- CD8 T cells
with rapamycin in vitro, an inhibitor of mTOR, and assessed effector cytokine
production following PMA/I stimulation. Morrbid-/- CD8 T cells were significantly
more sensitive to mTOR inhibition than WT cells as evidenced by TNF-α
production (Fig. 3.7g). Next, to determine if altered mTOR activity impacts the
expansion of Morrbid-/- CD8 T cells in vivo, we co-transferred WT P14 and
Morrbid-/- P14 CD8 T cells into congenically marked WT hosts, infected these mice
with LCMV, and treated these mice daily with PBS or low dose rapamycin. At day
8 post infection, rapamycin treatment had partially normalized the competitive
advantage of Morrbid-/- CD8 T cells (Fig. 3.7h), demonstrating that Morrbid-/- CD8
T cells are more dependent on mTOR activity.
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mTOR regulated protein translation and metabolism are altered in the absence of
Morrbid
Rapamycin has been described to potently inhibit mTORC1, although
mTOR2 inhibition has also been reported (Ballou and Lin, 2008). mTORC1 plays
a critical role in licensing protein translation through the phosphorylation of
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP) and S6
Ribosomal Protein (S6). We observed a significant increase in the phosphorylation
of S6 in Morrbid-/- CD8 T cells in response to TCR stimulation plus IFN-β treatment
(Fig. 3.7i). Using incorporation of homopropargylglycine (HPG), a methionine
analogue that can be fluorescently labeled in downstream processing, we also
observed an increase in total protein synthesis in the absence of Morrbid following
stimulation (Fig. 3.7j). In addition to translational regulation, mTORC1 is a central
regulator of CD8 T cell metabolism (Buck et al., 2015). To determine whether
glycolytic function or mitochondrial respiration were impacted in the absence of
Morrbid, we performed a mitochondrial respiration and glycolysis stress test. In
vitro differentiated WT and Morrbid-/- effector CD8 T cells, did not demonstrate
any difference in glycolysis or glycolytic capacity; however, Morrbid-/- effectors
demonstrated a significantly higher level of basal respiration and ATP production
(data not shown, Fig. 3.7k). mTORC1 has been described to drive mitochondrial
biogenesis through PGC1-α (Buck et al., 2015); thus, we are currently investigating
if mitochondrial mass and/or mitochondrial potential is altered in the absence of
Morrbid. Together, our data demonstrate that the AKT-mTOR pathway is
dysregulated in Morrbid-/- CD8 T cells.
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Figure 3.7. AKT-mTOR dysregulation in the absence of Morrbid impacts CD8
T cell activity and expansion
a) GSEA of curated Hallmark PI3K-AKT-mTOR signaling in WT and Morrbid-/- CD8 T
cells under the indicated stimulation conditions. b) Western blot and c) phosphoflow
gMFI for pS473 AKT in WT and Morrbid-/- CD8 T cells at the indicated timepoints
following stimulation with αCD3/αCD28 and IFN-β (n=3 mice per phosphoflow group,
representative of 2 indep exps). d) Intracellular Ca2+ flux in WT and Morrbid-/- CD8 T
cells as assessed by the ratiometric dye Indo-1. Arrow indicates the addition of
ionomycin. e) Western blot and f) phosphoflow gMFI for pT202/Y204 ERK1/2 in WT and
Morrbid-/- CD8 T cells at the indicated timepoints following stimulation with αCD3/αCD28
and IFN-β (n=3 mice per phosphoflow group, representative of 2 indep exps). g) TNF-α
production of PMA/I stimulated WT and Morrbid-/- CD8 T cells following pretreatment
with the indicated doses of rapamycin (n=3 mice per group). h) Ratio of Morrbid-/- to WT
frequency of donor cells at day 8 following co-transfer and infection with LCMV Cl13 in
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mice treated daily with either PBS or 75µg/kg rapamycin (n=4-5 mice per group). i)
Phosphoflow gMFI for pS235/236 ribosomal S6 in WT and Morrbid-/- CD8 T cells at the
indicated timepoints following stimulation with αCD3/αCD28 and IFN-β (n-3 mice per
group, representative of 2 indep exps). j) Frequency of incorporation of HPG in 3 hour
stimulated WT and Morrbid-/- CD8 T cells with or without cyclohexamide (CHX) (n=3
mice per group). k) Oxygen consumption rate in WT and Morrbid-/- in vitro differentiated
effector CD8 T cells treated with the indicated compounds (n=3 independently
differentiated replicates). Error bars show s.e.m. *P<0.05, **P<0.01, ***P<0.001 (FDR a;
two-sided t-test b-k).
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Morrbid RNA is enriched in CD8 T cell cytoplasm
As described above, Bcl2l11-deficiency did not appear to influence CD8 T
cell effector function, and Morrbid-locus deficiency did not result in any other
significant changes within 2 Mbs in cis. We therefore sought to understand how
the RNA itself might directly impact CD8 T cell expansion and function. As such,
we first more thoroughly characterized the RNA isoforms produced from this locus.
Using both 5’ and 3’ rapid amplification of cDNA ends, we identified 2 distinct RNA
transcripts produced in CD8 T cells following stimulation with αCD3/αCD28 and
IFN-β (Fig. 3.8a-d). Using probes targeting both of these Morrbid isoforms, we
next performed RNA florescent in situ hybridization (FISH). In contrast to the
predominantly nuclear staining that we observed in short-lived myeloid cells,
Morrbid RNA was highly enriched in the cytoplasm of CD8 T cells (Fig. 3.8e). To
further validate and quantify this localization pattern, we performed subcellular
RNA localization, and indeed found that both isoforms of Morrbid were highly
enriched in the cytoplasm of CD8 T cells (Fig. 3.8f). These results suggest that
Morrbid may control CD8 T cell activation through direct cytoplasmic rather than
nuclear interactions; thus, we are currently pursuing cytoplasmic binding partners
of Morrbid RNA.
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Figure 3.8. Morrbid RNA is enriched in the cytoplasm
a) Schematic of the Morrbid locus and its annotated exons. b) Day8 post LCMV P14 CD8
T cell RNAseq reads that map to the Morrbid locus (GSE88987). Lines indicate reads
spanning two locations. c) 5’ and d) 3’ rapid amplification of cDNA ends (RACE) of the
Morrbid locus from CD8 T cells stimulated with αCD3/αCD28/IFN-β. Arrows indicate genespecific primers and ticks opposite the arrows represent the end sequence of individual
clones. e) Morrbid RNA FISH in sorted WT and Morrbid-/- CD8 T cells stimulated with
αCD3/αCD28/IFN-β. f) qPCR for the indicated transcripts in the cytoplasmic,
nucleoplasmic, and chromatin bound subcellular fractions of WT CD8 T cells stimulated
with αCD3/αCD28/IFN-β (n=3 mice). Error bars show s.e.m. *P<0.05, **P<0.01,
***P<0.001 (one-way ANOVA with Tukey post-hoc).
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DISCUSSION
Here we show that the lncRNA Morrbid is induced in CD8 T cells following
TCR and type I IFN stimulation, and localizes to the cytoplasm. Following viral
infection, CD8 T cells deficient for the Morrbid locus expand to greater numbers
and fail to appropriately contract. Additionally, Morrbid-deficient CD8 T cells exhibit
a hyperactive effector profile and a loss of naïve cell homeostasis, both in a cellintrinsic manner (Fig 3.9). In contrast to short-lived myeloid cells, Morrbid-deficient
CD8 T cells express less Bcl2l11 following stimulation, which likely accounts for
some of the alterations in CD8 T cell contraction (Wojciechowski et al., 2006); yet,
our initial studies also suggest that the enhanced expansion and effector function
of Morrbid-deficient CD8 T cells may be Bcl2l11 independent. For example, AKTmTOR signaling is dysregulated in Morrbid-/- CD8 T cells, and AKT-mTOR
signaling is known to impact CD8 T cell expansion, effector function, and naïve
cell homeostasis (Kim et al., 2012; Yang et al., 2011). The parallels between
Morrbid and AKT-mTOR suggest that Morrbid may regulate CD8 T cell function
through modulation of AKT-mTOR activity. We are continuing to work to better
understand at the molecular level how Morrbid impacts CD8 T cell activation,
expansion, and function.
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Figure 3.9. Working model for the role of the Morrbid locus in CD8 T cells
In CD8 T cells, Morrbid is rapidly induced following TCR, costimulation, and type I
IFN signalling, and localizes to the cytoplasm. Following stimulation in the absence
of the Morrbid locus, these cells exhibit greater expansion, decreased contraction,
and augmented effector function. Additionally, these Morrbid locus-deficient cells
demonstrate increased AKT-mTOR activity and decreased Bcl2l11 expression.
Work is underway to determine the contribution of Morrbid RNA to this phenotype
and the molecular mechanism through which this locus controls CD8 T cell
function.
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Many outstanding questions remain regarding Morrbid’s control of CD8 T
cell function. Critically, we have yet to separate the impact of the Morrbid locus
from that of its RNA product on CD8 T cell function. Primary murine T cells respond
poorly to most transfection methods limiting the use of siRNA and antisense
oligonucleotides targeting this lncRNA in these cells. On the other hand, shRNAbased targeting is well established in murine T cells (Chen et al., 2014), and
represents one approach to target this lncRNA in this setting. Using shRNAs
targeting Morrbid, work is underway to test if this RNA is necessary for appropriate
CD8 T cell expansion and function. Of note, CD8 T cell transduction requires preactivation of these cells; thus, we will be unable to assess the effect of Morrbid
RNA on priming. We are also in the process of developing the tools to overexpress
Morrbid RNA in CD8 T cells deficient for the Morrbid locus, to determine if
expression of the RNA is sufficient to rescue the Morrbid locus-deficient
phenotype. It is likely the phenotype we observe is a combination of both RNAdependent and RNA-independent mechanisms, and these tools will help us to
disentangle their contributions.
Some lncRNAs have been described to regulate the expression of
neighboring genes (Maass et al., 2012; Wang et al., 2011, 2015; Zhang et al.,
2014). For example, in short-lived myeloid cells, Morrbid RNA regulates short-lived
myeloid survival through the repression of its gene neighbor Bcl2l11. In contrast to
short-lived myeloid cells, CD8 T cells deficient for the Morrbid locus express less
Bcl2l11 after stimulation. The regulation of Bcl2l11 is consistent with one
hypothesis regarding mechanism for the effects of Morrbid deficiency – survival.
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Following viral infection, Morrbid-deficient CD8 T cells expand to greater numbers
and maintain these increased numbers over time. We did not observe a difference
in early proliferation or trafficking, and although we cannot rule out the contribution
of these processes to the increase in CD8 T cell numbers, these data are highly
suggestive that increased survival drives the increased expansion of Morrbiddeficient CD8 T cells. Given that Bcl2l11 is the only significant transcriptional
change that we observed within 2 Mbs of the Morrbid locus, and is a known potent
pro-apoptotic molecule in CD8 T cells, it represents the most likely contributor to
our phenotype.
The Morrbid locus may augment Bcl2l11 transcription in an RNA-dependent
manner, through transcription across the Morrbid locus, or it may simply represent
a proxy for important DNA regulatory elements important for Bcl2l11 expression.
Although feasible, it is unlikely that the same RNA has both RNA-intrinsic
repressive and enhancer activity; nevertheless, we plan to address this possibility
using Morrbid shRNA knockdown and Morrbid RNA overexpression. From our
previous work in short-lived myeloid cells, there is a strong association between
the Bcl2l11 promoter and the Morrbid locus as determined by chromatin
conformation capture (3C). Using a previously published ATAC-seq data, we also
observed that the Morrbid locus is largely inaccessible in naïve CD8 T cells, but
several DNA elements open up following activation, including the DNA site we
previously found to associate with Bcl2l11 (GSE86797; data not shown). It is
possible that the act of transcription through the Morrbid locus influences the
association of these two loci and subsequently Morrbid’s regulation of Bcl2l11. It
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is also feasible that Morrbid RNA transcription is simply a proxy for activity, and
that Morrbid’s control of Bcl2l11 is entirely DNA dependent. Studies examining the
association of these loci in CD8 T cells before and after stimulation, as well as in
the context of a transcriptionally terminating synthetic polyA cassette, will help our
understanding of how the Morrbid locus promotes Bcl2l11 expression in CD8 T
cells.
Some lncRNAs have been described to regulate the expression of genes in
trans (Carpenter et al., 2013; Huang et al., 2015; Rinn et al., 2007; Wang et al.,
2014). Although Bcl2l11 expression is decreased in the absence of Morrbid, a
number of other loci in trans were altered in the absence of Morrbid. It is possible
that decreased Bcl2l11 expression might indirectly contribute to this phenotype;
however, genes known to be upregulated in activated Bcl2l11-deficient CD8 T cells
were not enriched in activated Morrbid-/- CD8 T cells (see Fig. 3.6e). These results
support the alternative hypothesis that Morrbid-deficient CD8 T cells hyperactivity
is independent of Bcl2l11. The contraction phase of Morrbid-deficient CD8 T cells
closely mirrors that of Bcl2l11-deficient CD8 T cells. Nevertheless, to date no
Bcl2l11-deficient studies have reported increased CD8 T cell expansion or effector
function (Grayson et al., 2006; Ludwinski et al., 2009; Wojciechowski et al., 2006).
Additionally, the dysregulation of AKT-mTOR and the fact that rapamycin can
largely normalize the phenotype is highly suggestive of Bcl2l11 independence. As
discussed above, rapamycin is known to impact mTORC2 activity (Ballou and Lin,
2008), and consequently the AKT-dependent inactivation of FOXO3 (Stahl et al.,
2002). FOXO3 has been previously described to negatively regulate primary CD8
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T cell expansion, but not memory formation (Togher et al., 2015), which closely
parallels the Morrbid-deficient CD8 T cell phenotype. Studies examining the impact
of Bcl2l11-deficiency and Bcl2l11-Morrbid double-deficiency on CD8 T cell function
will certainly help to disentangle the contribution of Bcl2l11 to our observed
phenotype.
It is possible that Bcl211 and Morrbid both contribute to the observed
phenotype. These loci may even act synergistically. For example, Morrbid RNA
deficiency might promote strong CD8 T cell activation, which in isolation would
result in CD8 T cell apoptosis; however, due to the reduction in Bcl2l11 through
loss of important DNA regulatory elements in the Morrbid locus, these hyperactivated cells survive and thus CD8 T cells activation is even more pronounce.
Attempts to separate the contributions of Morrbid RNA and Bcl2l11 to the
phenotype will need to be wary of this possibility, as knockdown studies of Morrbid
RNA may indeed result in CD8 T cell hyperactivity, but in the context of
unperturbed Bcl2l11 expression we may only observe cell death. This potential
situation highlights how survivorship bias, studying only the cells that are alive to
be studied, can confound an interpretation of a larger biological effect.
In summary, these studies demonstrate that the lncRNA Morrbid is induced
in CD8 T cells by TCR engagement in combination with type I IFN stimulation, and
that the Morrbid locus restrains CD8 T cell expansion and hyperactivity in these
cells. Work is ongoing to determine the contribution of Morrbid RNA and Bcl2l11
to this phenotype, as well as the molecular mechanisms of this regulation.
Importantly, these studies establish Morrbid’s potential to be induced in cell types
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other than short-lived myeloid cells, where it can function to control processes
other than Bcl2l11 repression.
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Chapter 4 – Discussion: Thoughts on the role of Morrbid and
other lncRNAs in immune responses
Summary
The data presented in this thesis:
•

Identify the lncRNA Morrbid as a fundamental regulator of short-lived myeloid
lifespan at homeostasis. Morrbid RNA finely tunes the lifespan of these cells in
response to common β-chain cytokines through recruitment of PRC2 and
repression of it’s pro-apoptotic neighbor Bcl2l11 in cis (Chapter 2).

•

Uncover Morrbid induction in non-short-lived myeloid cells following
inflammatory stimuli. CD8 T cells upregulate Morrbid expression following TCR
and type I IFN stimulation (Chapter 3).

•

Demonstrate the functional versatility of the Morrbid locus in controlling
processes other than Bcl2l11 repression. Morrbid locus-deficient CD8 T cells
exhibit increased expansion, enhanced effector function, loss of naïve
homeostasis (Chapter 3).
The following discussion explores some of the implications of these data, future
directions, as well as the roles of lncRNAs in immune homeostasis.
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On the origin of Morrbid and other lncRNAs
Studies have shown that several evolutionary trajectories of lncRNAs exist.
First, lncRNAs can develop from protein-coding genes, termed lncRNA
pseudogenization. For example, Xist was found to derive from the protein-coding
gene Lnx3 that had acquired frame-disrupting mutations (Duret et al., 2006). The
order of pseudogenization in regards to duplication and mutation is often difficult
to discern. Second, lncRNAs can derive from chromosomal rearrangements from
untranscribed and previously well-separated regions. A lncRNA highly expressed
in dog testis appears to have arisen this way (Ponting et al., 2009). Third, similar
to pseudogenization, lncRNAs can be generated through retrotransposition of
other noncoding elements. For example, the mouse lncRNA nuclear enriched
abundant transcript 2 (Neat2) appears to have arisen through this mechanism, as
it is paralogous to non-exonic sequences elsewhere in the mouse genome
(Ponting et al., 2009). Finally, lncRNAs can emerge by chance through
transposable element driven mutagenesis. Importantly, evolution and conservation
of lncRNAs is incredibly difficult to fully appreciate as the sequence constraints for
RNA folding and structure are more lenient than those for protein folding, and
lncRNAs highly conserved at the structural level may appear poorly conserved at
the sequence level.
The Morrbid locus appears to have rapidly evolved following the
development of Bcl2l11. Mitochondrial-dependent apoptosis is ancient in origin
and a documented potent apoptotic pathway in all vertebrates. The importance of
mitochondrial outer membrane permeabilization (MOMP) in the apoptosis of
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invertebrates is less certain and a topic of current study (Oberst et al., 2008).
Interestingly, Bcl2l11 arose rapidly following the development of MOMPdependent apoptosis, and by comparative genomics analysis exists as early as
Coelacanths, the oldest known living lineage of tetrapods (Herrero et al., 2016).
Remarkably, a cis-located transcriptionally active Morrbid locus quickly followed
suit and appeared as early as the anole lizard, a closely related tetrapod (data not
shown). Although we do not know whether Morrbid performs a similar function in
these other species (i.e. control of Bcl2l11 expression), the close co-evolution of
Bcl2l11 and Morrbid highlights the fundamental relationship between these two
loci.
We and another group recently noted that humans have 2 copies of
MORRBID at distinct locations on chromosome 2 (data not shown, (Nötzold et al.,
2017)). It is unclear where in evolution this duplication event occurred; however,
the exon 1-2 isoform of MORRBID is clearly present at 2 locations over 25 Mbs
from one another on chromosome 2. The biological function of this duplicated
MORRBID (LINC00152) is largely uncertain, although in HELA cells LINC00152
impacted cell cycle progression of this cell line (Nötzold et al., 2017). As a
nonfunctional sequence would be expected to accumulate mutations or be lost
over the course of evolution, this duplication event and its high degree of exonic
sequence conservation support the functional importance of MORRBID.
Additionally, this duplication event is suggestive of a trans-dependent effect of
MORRBID. It is possible that both MORRBID and LINC00152 only regulate genes
near their own loci in cis, and that the MORRBID sequence was coopted for this
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cis-regulatory function. Nevertheless, the duplication of MORRBID at two distinct
loci implies that its function may not depend on its own genomic location.
Additionally, HELA LINC00152 and murine CD8 T cell Morrbid are both enriched
in the cytoplasm. Together, these data suggest that Morrbid may have the capacity
to function in trans.
Why and how a single locus would perform such disparate functions in
different cell types is an interesting question. For example, in mice we found that
Morrbid regulates short-lived myeloid lifespan at homeostasis through repression
of Bcl2l11 in cis. In contrast, in CD8 T cells Morrbid is induced following infection,
does not repress Bcl2l11 (actually leads to increases in Bcl2l11 expression), and
controls CD8 T cell expansion and effector function through a yet to be defined
mechanism. From preliminary data, several potential explanations exist for this
dichotomy. To begin, short-lived myeloid cells highly express an exon 1-2 isoform,
and do not appear to significantly express additional Morrbid isoforms (data not
shown). In contrast, CD8 T cells express both an exon 1-2 isoform, as well as an
exon 1-3-5 isoform (Fig. 3.8). Thus, it is possible that differential splicing of Morrbid
may explain its disparate biological functions. Additionally, different cell types have
different trancriptomes and proteomes; thus, alterations in Morrbid’s interactome
may dramatically influence its biological function. The most obvious consequence
of this altered interactome is the cell-type specific localization of Morrbid. When
using the same protocol and assessing the same isoform, we found that Morrbid
was predominantly bound to chromatin in short-lived myeloid cells whereas it was
enriched in the cytoplasm in CD8 T cell. This difference in localization would further
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alter the interactome of Morrbid and markedly alter its potential function. Finally, it
is possible that Morrbid’s cis function in short-lived myeloid cells is sequence
independent. We found, through a promoter deletion and multiple knockdown
studies, that Morrbid repression of Bcl2l11 in these cells is dependent on
transcription and the transcript. Moreover, we found that Morrbid associates with
PRC2 through both PAR-CLIP and RIP studies; yet, as discussed in Chapter 2,
PRC2 promiscuously binds RNA, and our data do not demonstrate a sequence
dependent function of Morrbid in these cells. Thus, it is possible that Morrbid
represses Bcl2l11 in cis in a sequence-independent manner, and that its additional
function in CD8 T cells is mediated through its intrinsic RNA sequence. Countless
other possibilities exist to explain this dichotomy in function. To begin to address
these possibilities experimentally, we plan to better characterize the molecular
mechanism of action of Morrbid in CD8 T cells and determine whether its impact
in these cells is RNA dependent.

Control of nuclear organization by lncRNAs
Evidence has recently emerged that lncRNAs can regulate the spatial
localization of proteins, RNAs, and genomic sites in the nucleus. For example, Xist
is important in local chromatin structure changes (Cerase et al., 2015); however,
at a macro-nuclear level Xist is also required for targeting of the inactive Xchromosome to the inner nuclear membrane, which is critical for efficient Xchromosome inactivation (Chen et al., 2016). Another example of structural
regulation is the lncRNA Firre, which drives colocalization of its own loci with
several other specific loci on mouse chromosomes 2, 9, 15, and 17 (Hacisuleyman
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et al., 2014), again demonstrating the role of lncRNAs in physically shaping the
structure of the nucleus. It is possible that Morrbid influences nuclear architecture
on a macro-scale; however, the fact that genetic reduction of Bcl2l11 rescues
short-lived myeloid lifespan suggests that this phenotype is mostly dependent on
Morrbid’s regulation of Bcl2l11.
At the local level, transcription of lncRNAs has been described to influence
the expression of neighboring genes in cis (Engreitz et al., 2016), as discussed in
Chapter 1. Of note, transcription is also known to influence CTCF and cohesion
positioning, two factors critical for chromatin loop formation and the spatial
organization of DNA (Busslinger et al., 2017). As such, we reason that many cis
acting lncRNAs function through the control of chromosome looping. For example,
in plants the lncRNA Apolo was found to loop and repress its neighboring gene
protein serine/threonine kinase PINOID (PID) in a transcription dependent manner
(Ariel et al., 2014). Similar mechanisms are likely utilized by many lncRNAs.
From our results, we know that Morrbid RNA associates with the Bcl2l11
promoter, and that the Morrbid locus and its transcript are required for Bcl2l11
repression. Of note, we do not know whether this loop formation is required for
Morrbid repression of Bcl2l11. We can address this question by genetically
deleting this contact point using CRISPR/Cas9. If this contact is indeed important
for Bcl211 repression, we postulate that Morrbid transcription and its RNA are
important for the formation of this chromatin loop. We can rapidly test this
hypothesis by examining loop formation in the presence of the transcription
inhibitor actinomycin D, or genetically, using a synthetic polyA. Because Morrbid
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RNA is required for Bcl2l11 repression, as evidenced by multiple knockdown
studies presented in Chapter 2, it is possible that the RNA itself is important for the
Morrbid-Bcl2l11 chromosomal association. Just as the Xist transcript is important
for tethering the X-chromsome to the lamin B receptor (Chen et al., 2016), Morrbid
RNA may be important for tethering Morrbid and Bcl2l11 together. Given the shear
number of lncRNAs whose expression is dynamically regulated and associated
with the expression of cis-positioned genes, we postulate that lncRNA control of
3D chromatin architecture is a pervasive mechanism of lncRNA mediated
transcriptional control.

Morrbid and the unexplored world of micropeptides
An emerging, but largely unexplored category of lncRNA mechanisms is
that of micropeptides. This RNA-dependent, but not RNA-intrinsic, category is
simply defined as open reading frames (ORFs) smaller than 100 amino acids that
produce protein (Crappé et al., 2014). Interestingly, this class of molecules is well
established to perform critical biological functions in plants and flies. For example,
soybeans mutant for the micropeptide early nodulin 40 (Enod40) are unable to
develop root nodules. This class of molecules is of particular interest because
Morrbid RNA is enriched in the cytoplasm of CD8 T cells. Additionally, according
to a recently published dataset of polysome fractionated CD8 T cells following
LCMV infection, Morrbid is predominantly polysome bound (data not shown, data
from (Araki et al., 2017)). As discussed in Chapter 1, approximately 70% of
cytoplasmic lncRNAs have more than 50% of their cytoplasmic copies associated
with polysome fractions (Carlevaro-Fita et al., 2016). Although these results
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suggest promiscuity in targeting of cytoplasmic RNAs to the ribosome, they also
imply that thousands of RNAs known to contain small ORFs are poised for
translation. Whether some ribosome-associated lncRNAs produce peptide, and
whether these peptides have biological function, has yet to be determined. Similar
to the class of lncRNAs that function through the act of transcription, it seems likely
that many of the small ORFs impact translational regulation through the act of
translation.
In regards to Morrbid, both splice isoforms contain several small ORFs with
strong predicted Kozak scores (data not shown). Using HA tagged ORFs, work in
our laboratory is ongoing to determine if any of these short Morrbid ORFs produce
peptide. Of note, this “bottom up” approach largely disregards the intricacies of
non-canonical translation initiation, and thus likely overlooks many potential
micropeptides. In parallel we have undertaken a “top down” approach using high
resolution proteomics data of activated CD8 T cells specifically to identify
micropeptides produced by CD8 T cells in an unbiased manner. Preliminary data
suggests that many annotated noncoding RNAs produce peptide; however, the
functional significance of these peptides has yet to be studied.

Moving forward: technical challenges in dissecting lncRNA mechanisms in
vivo
In general, although high-throughput sequencing has allowed for great
progress to be made in profiling immune cell lncRNA expression patterns (Fig.
4.1a), the functional characterization of these lncRNAs in vivo has lagged far
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behind. Much of this delay can be attributed to the difficulty in separating the role
of the genomic lncRNA loci from that of its RNA products. For example, many
groups including ours have deleted full lncRNA loci to test lncRNA functionality
((Eißmann et al., 2012; Penny et al., 1996); Fig. 4.1b). While this deletion
approach is a rapid way to initially screen functional lncRNA loci, especially with
the efficiency of the CRISPR/Cas9 system, it does not separate any of the 4
lncRNA mechanism categories discussed above: functional RNAs, transcriptiondependent, proxy signals for cis-regulatory elements, and bioactive peptides. As
such, additional complementary experimental approaches need to be taken to
disentangle the functionality of these lncRNAs (Bassett et al., 2014).
RNA interference (RNAi)-based techniques, in particular short-hairpin
RNAs (shRNAs), are an important addition to the experimental arsenal of lncRNA
biologists as they allow for stable targeting of specific RNAs (Fig. 4.1c). Of note,
nuclear RNAi targeting is less well understood (Castel and Martienssen, 2013;
Gagnon et al., 2014); thus, RNAi techniques are most well suited for testing the
RNA-dependence of cytoplasmic lncRNAs. Antisense oligonucleotides (ASOs),
provide an alternative post-transcriptional RNA targeting method (Dias and Stein,
2002), and their nuclear RNA targeting is significantly better characterized.
Unfortunately, this methodology cannot be used to generate stable transgenic
lines. To test transcription-dependent lncRNA function, additional genetic
approaches can be taken to insert transcriptional terminator sequences
((Anderson et al., 2016; Engreitz et al., 2016); Fig. 4.1d). Targeted deletion of DNA
elements within the lncRNA locus, such as the lncRNA promoter, may help to
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expose the lncRNA as a proxy for these important cis-regulatory elements. As with
all genetic approaches, investigators must be vigilant and control for disruption of
important DNA regulatory elements and inadvertent impact of inserted DNA
elements. Importantly, it is not possible to predict lncRNA function from expression
levels and sequence composition with current bioinformatics tools, especially with
little known about conserved lncRNA motifs and secondary structures. Thus, a
combination of the empiric approaches above must be taken and interpreted in the
context of each lncRNA to accurately characterize its functionality.

Figure 4.1. Moving forward: technical challenges in dissecting lncRNA mechanisms in
vivo.
In vivo functional testing of lncRNAs remains challenging but is critical to understanding
their relevance in the immune system. a) Cell type-specific lncRNA expression profiles can
be generated from RNA-seq on purified cell populations or publicly available datasets. b)
The functional relevance of these loci encoding these lncRNAs can be quickly and easily
assessed by generating genomic deletions using the CRISPR/Cas9 system. c) RNAdependence of functional lncRNA loci can be assessed using short-hairpin (sh)RNAs and
antisense oligonucleotides (ASOs). d) Transcriptional dependence can be determined by
insertion of a premature poly(A) cassette using CRISPR/Cas9. Figure from Mowel and
Kotzin et al. 2017.
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Concluding remarks
In summary, our studies of Morrbid-mediated immune regulation provide
important insight into a growing literature that lncRNAs are critical epigenetic and
transcriptional regulators that allow cells to adapt their gene expression profiles to
cues within their extracellular environment, in a cell-type specific manner. It is
becoming clear that the diverse cell types of the innate and adaptive immune
system are no exception, and that lncRNAs are key regulatory molecules of
immune cell gene expression programs in response to microbial and tissuederived cues. Although much progress has been made in cataloging lncRNAs
expressed in the immune system and in assessing their functional impact, there
still exists a large gap in our understanding of how these lncRNAs function at the
molecular level in the context of immune responses. The development of new
experimental and bioinformatic technologies will be paramount in increasing our
understanding of lncRNA biology. In particular, novel techniques directed towards
predicting and interrogating the structure of lncRNAs will be essential as they will
help to uncover lncRNA motifs and structures that ultimately dictate the localization
and interactomes of these molecules. Additionally, novel techniques to address
the impact of lncRNAs on higher order 3D chromatin organization will help uncover
parallels between certain lncRNAs and potentially new principles of lncRNA
function. Ultimately, better understanding of lncRNA function in the immune
system will expose new means to augment protective immunity, quell excess
inflammation, and promote tissue homeostasis.
Figures and certain excerpts in Chapter 4 were previously published in Mowel and Kotzin et al. 2017.
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METHODS
Mice
All mice were bred and maintained under pathogen-free conditions at an American
Association for the Accreditation of Laboratory Animal Care accredited animal
facility at the University of Pennsylvania or Yale University. Mice were housed in
accordance with the procedures outlined in the Guide for the Care and Use of
Laboratory Animals under an animal study proposal approved by an institutional
Animal Care and Use Committee. Male and female mice between 4 and 12 weeks
of age were used for all experiments. Littermate controls were used whenever
possible.
C57BL/6 (WT) and B6.SJL-Ptprca Pepcb/Boy (B6.SJL) mice were purchased from
The Jackson Laboratory. We generated Morrbid-deficient mice and the in cis and
in trans double heterozygous mice (Morrbid+/-, Bcl2l11+/-) mice using the
CRISPR/Cas9 system as previously described (Henao-Mejia et al., 2016). In brief,
to generate Morrbid-deficient mice, single guide RNAs (sgRNAs) were designed
against regions flanking the first and last exon of the Morrbid locus. Cas9-mediated
double-stranded DNA breaks resolved by non-homologous end joining (NHEJ)
ablated the intervening sequences containing Morrbid in C57BL/6N one-cell
embryos. The resulting founder mice were Morrbid-/+, which were then bred to
wild-type (WT) C57BL/6N and then intercrossed to obtain homozygous Morrbid-/mice. One Morrbid-deficient line was generated. To control for potential off-target
effects, mice were crossed for at least 5 generations to WT mice and then
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intercrossed to obtain homozygosity. Littermate controls were used when possible
throughout all experiments.
To generate the in cis and in trans double heterozygous mice (Morrbid+/-,
Bcl2l11+/-) mice, we first obtained mouse one-cell embryos from a mating between
Morrbid-/- female mice and WT male mice. As such, the resulting one-cell embryos
were heterozygous for Morrbid (Morrbid+/-). We then micro-injected sgRNAs
designed against intronic sequences flanking the second exon of Bcl2l11, which
contains the translational start site/codon, into Morrbid-/+ one-cell embryos. Cas9mediated double-stranded DNA breaks resolved by NHEJ ablated the intervening
sequences containing the second exon of Bcl2l11 in Morrbid+/- (C57BL/6N) onecell embryos, generating founder mice that were heterozygous for both Bcl2l11
and Morrbid (Bcl2l11+/-; Morrbid-/+). Founder heterozygous mice were then bred
to WT C57BL/6N to interrogate for the segregation of the Morrbid-deficient and
Bcl2l11-defient alleles. Pups that segregated such alleles were named in trans and
pups that did not segregate were labeled in cis. One line of in cis and in trans
double heterozygous mice (Bcl2l11+/-; Morrbid-/+) lines were generated. To
control for potential off-target effects, mice were crossed for at least 5 generations
to WT (C57BL/6N) mice (for in cis) and to Morrbid-/- mice (for in trans) to maintain
heterozygosity. To determine genetic rescue, samples from mice containing
different permutations of Morrbid and Bcl2l11 alleles were analyzed in a blinded
manner by a single investigator not involved in the breeding or coding of these
samples.
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To generate transgenic P14 expressing mice, the indicated genetic backgrounds
were crossed to B6;D2-Tg(TcrLCMV)327Sdz/JDvsJ mice from The Jackson
Laboratory. P14 expression was assessed phenotypically by flow cytometry.

Flow cytometry staining, analysis, and cell sorting
Cells were isolated from the indicated tissues (blood, spleen, bone marrow,
peritoneal exudate, adipose tissue). Red blood cells were lysed with ACK. Singlecell suspensions were stained with CD16/32 and with indicated fluorochromeconjugated antibodies. If run live, cells were stained with 7-AAD (7-aminoactinomycin D) to exclude non-viable cells. Otherwise, prior to fixation, Live/Dead
Fixable Violet Cell Stain Kit (Invitrogen) was used to exclude non-viable
cells. Active caspase staining using Z-VAD-FMK (CaspGLOW, eBiosciences) was
performed according to the manufacturer's specifications. Apoptosis staining by
annexin V+ (Annexin V Apoptosis Detection kit) was performed according to the
manufacturer's recommendations. BrdU staining was performed using BrdU
Staining Kit (eBioscience) according to the manufacturer’s recommendations.
Detection of phosphorylated Akt473 (p-Akt473), p-S6235/236, and p-ERK202/204 was
performed using paraformaldehyde and methanol permeabilization. Stimulation
conditions for phosphoflow were identical to those for western blotting described
below. L-homopropargylglycine (HPG) incorporation was performed as previously
described using Click-iT HPG Alexa Fluor 488 Protein Synthesis Assay Kit
(ThermoFisher)(Araki et al., 2017). For BCL2L11 staining, cells were fixed for 15
min in 2% paraformaldehyde solution, and permeabilized with flow cytometry
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buffer supplemented with 0.1% Triton X-100. All flow cytometry analysis and cellsorting procedures were done at the University of Pennsylvania Flow Cytometry
and Cell Sorting Facility using BD LSRII cell analyzers and a BD FACSAria II sorter
running FACSDiva software (BD Biosciences). FlowJo software (v. 10 TreeStar)
was used for data analysis and graphic rendering.

Adoptive transfer and LCMV infection
CD8 T cells were isolated from peripheral blood or spleens of naïve mice of the
indicated genetic background. For spleen isolation, P14 cells were purified by CD8
T cell negative selection (StemCell Technologies). The indicated number of P14 T
cells was transferred into naïve recipient mice of the indicated genetic and
congenic background. For acute LCMV Armstrong infection, mice were infected
intraperitoneally with 2 x 105 PFU. For chronic LCMV Clone 13 infection, mice were
infected intravenously with 2 x 106. Viral titers were measured as previously
described (Wherry et al., 2003).

Ca2+ flux assay
P14 WT and Morrbid-/- CD8 T cells were loaded with 2.5μM Indo-1 for 30 min at
37°C in Ca2+ replete media. Cells were washed and subsequently stained for
surface expression markers. Prior to analysis cells were washed and transferred
into either Ca2+-depleted or Ca2+-sufficient media, warmed to 37°C, and analyzed
by flow cytometry using a UV laser before and after Ionomycin stimulation.
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Western blotting
In Chapter 2, 1 x106 WT and Morrbid-deficient neutrophils sorted from mouse bone
marrow were assayed for BCL2L11 protein expression by Western blotting (Bim
C34C5 Rabbit mAb, Cell Signaling) as previously described.
In Chapter 3, Sorted CD62L+CD44lo WT and Morrbid-/- splenic CD8 T cells were
serum starved for 2 hours, incubated with 10μg/mL biotinylated αCD3 (145-2C11),
αCD28 (37.51), and αCD8 (53-6.7) for 1 min, and stimulated with 50 μg/mL of
streptavidin and 20ng/mL IFN-β1 (Biolegend) for the indicated period of time.

ChIP-qPCR
2 x106 WT and Morrbid-deficient neutrophils sorted from mouse bone marrow were
cross-linked in a 1% Formaldehyde solution for 5 min at room temperature while
rotating. Crosslinking was stopped by adding glycine (0.2M in 1x PBS) and
incubating on ice for 2 min. Samples were spun at 2500g for 5 min at 4°C and
washed 4 times with 1x PBS. The pellets were flash frozen and stored at -80°C.
Cells were lysed, and nuclei were isolated and sonicated for 8 min using a Covaris
S220 (105 Watts, 2% Duty Cycle, 200 cycles per burst) to obtain approximately
200–500 bp chromatin fragments. Chromatin fragments were precleared with
protein G magnetic beads (New England BioLabs) and incubated with pre-bound
anti-H3K27me3 (Qiagen), anti-EZH2 (eBiosciences), or Mouse IgG1 (Santa Cruz
Biotechnology) antibody-protein G magnetic beads overnight at 4°C. Beads were
washed once in low-salt buffer (20 mM Tris, pH 8.1, 2 mM EDTA, 50 mM NaCl,
1% Triton X-100, 0.1% SDS), twice in high-salt buffer (20 mM Tris, pH 8.1, 2 mM
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EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS), once in LiCl buffer (10 mM
Tris, pH 8.1, 1 mM EDTA, 0.25 mM LiCl, 1% NP-40, 1% deoxycholic acid) and
twice in TE buffer (10 mM Tris-HCl, pH 8. 0, 1 mM EDTA). Washed beads were
eluted twice with 100 μL of elution buffer (1% SDS, 0.1 M NaHCO3) and decrosslinked (0.1 mg/ml RNase, 0.3 M NaCl and 0.3 mg/ml Proteinase K) overnight
at 65°C. The DNA samples were purified with Qiaquick PCR columns (Qiagen).
qPCR was carried out on a ViiA7 Real-Time PCR System (ThermoFisher) using
the SYBR Green detection system and indicated primers. Expression values of
target loci were directly normalized to indicated positive control loci, such as
MyoD1 for H3K27me3 and EZH2 ChIP analysis, and Actb for Pol II ChIP analysis.
ChIP-qPCR primer sequences are listed in Supplementary Table 1.

RIP-qPCR
107 immortalized bone marrow-derived macrophages (iBMDMs) were harvested
by trypsinization and resuspended in 2 ml PBS, 2 ml nuclear isolation buffer (1.28
M sucrose; 40 mM Tris-HCl pH 7.5; 20 mM MgCl2; 4% Triton X-100), and 6 ml
water on ice for 20 min (with frequent mixing). Nuclei were pelleted by
centrifugation at 2,500 G for 15 min. Nuclear pellets were resuspended in 1 ml RIP
buffer (150 mM Kcl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% NP40;
100 U/ml SUPERaseIn, Ambion; cOmplete EDTA-free protease inhibitor, Sigma).
Resuspended nuclei were split into two fractions of 500 μl each (for Mock and IP)
and were mechanically sheared using a dounce homogenizer. Nuclear membrane
and debris were pelleted by centrifugation at 13,000 RPM for 10 min. Antibody to
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EZH2 (Cell Signaling cat# 4905S; 1:30) or Normal Rabbit IgG (Mock IP,
SantaCruz; 10 μg) were added to supernatant and incubated for 2 hours at 4°C
with gentle rotation. 25 μL of protein G beads (New England BioLabs cat# S1430S)
were added and incubated for 1 hour at 4°C with gentle rotation. Beads were
pelleted by magnetic field, the supernatant was removed, and beads were
resuspended in 500 μl RIP buffer and repeated for a total of three RIP washes,
followed by one wash in PBS. Beads were resuspended in 1 ml of Trizol.
Coprecipitated RNAs were isolated, reverse transcribed to cDNA, and assayed by
qPCR for the Hprt and Morrbid-isoform1. Primer sequences are listed in
Supplementary Table 1.

PAR-CLIP analysis
EZH2

PAR-CLIP

dataset

(GSE49435)

was

analyzed

as

previously

described(Kaneko et al., 2014). Adapter sequences were removed from total
reads and those longer than 17 bp were kept. The Fastx toolkit was used to
remove duplicate sequences, and the resulting reads were mapped using BOWTIE
allowing for two mismatches. The four independent replicates were pooled and
analyzed using PARalyzer, requiring at least two T->C conversions per RCS.
LncRNAs were annotated according to Ensemble release 67.

Chromosome Conformation Capture (3C)
13 x106 WT bone marrow derived mouse eosinophils were fixed with 1%
formaldehyde for 10 minutes at room temperature, and quenched with 0.2M
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glycine on ice. Eosinophils were lysed for 3-4 hours at 4°C (50mM Tris pH 7.4,
150mM NaCl, 0.5% NP-40, 1% Triton X-100, 1X Roche complete protease
inhibitor) and dounce homogenized. Lysis was monitored by Methyl-green pyronin
staining (Sigma). Nuclei were pelleted and resuspended in 500ul 1.4X NEB3.1
buffer, treated with 0.3% SDS for one hour at 37°C, and 2% Triton X-100 for
another hour at 37°C. Nuclei were digested with 800 units BglII (NEB) for 22 hours
at 37°C, and treated with 1.6% SDS for 25 minutes at 65°C to inactivate the
enzyme. Digested nuclei were suspended in 6.125mL of 1.25X ligation buffer
(NEB), and were treated with 1% Triton X-100 for one hour at 37°C. Ligation was
performed with 1000 units T4 DNA ligase (NEB) for 18 hours at 16°C, and
crosslinks were reversed by proteinase K digestion (300 μg) overnight at 65°C.
The 3C template was treated with RNase A (300 μg), and purified by phenolchloroform extraction. Digested and undigested DNA were run on a 0.8% agarose
gel to confirm digestion. To control for PCR efficiency, two BACs spanning the
region of interest were combined in equimolar quantities and digested with 500
units BglII at 37°C overnight. Digested BACs were ligated with 100 units T4 Ligase
HC (Promega) in 60ul overnight at 16°C. Both BAC and 3C ligation products were
amplified by qPCR (Applied Biosystems ViiA7) using SYBR fast master mix (KAPA
biosystems). Products were run side by side on a 2% gel, and images were
quantified using ImageJ. Intensity of 3C ligation products was normalized to
intensity of respective BAC PCR product.

Listeria monocytogenes infections
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Mice were infected with 30,000 colony-forming units (CFUs) of Listeria
monocytogenes (Strain 10403s) intravenously (i.v.). Mice were weighed and
inspected daily. Mice were analyzed at day 4 of infection to determine the CFUs
of L. monocytogenes present in the spleen and liver.

Papain challenge
Papain was purchased from Sigma Aldrich and resuspended in at 1mg/ml in
Phosphate buffered Saline (PBS). Mice were intranasally challenged with 5 doses
of 20 μg papain in 20 μl of PBS or PBS alone every 24 hours. Mice were sacrificed
12 hours after the last challenge. Bronchoalveolar lavage was collected in two 1
mL lavages of PBS. Cellular lung infiltrates were collected after 1 hour digestion
in RPMI supplemented with 5% FCS, 1 mg/ml Collagenase D (Roche) and 10
μg/ml DNase I (Invitrogen) at 37°C. Homogenates were passed through a cell
strainer and infiltrates separated with a 27.5%, Optiprep gradient (Axis-Shield) by
centrifugation at 2750 rpm for 20 min. Cells were removed from the interface and
treated with ACK lysis buffer.

Bone marrow chimeras
In Chapter 2, congenic C57BL/6 WT bone marrow expressing CD45.1 and CD45.2
and Morrbid-deficient bone marrow expression CD45.2 was mixed in a 1:1 ratio
and injected into C57BL/6 hosts irradiated twice with 5 Gy 3 hours apart that
express CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ). Mice were analyzed between 4-9
weeks after injection. In Chapter 3, 5000 sorted WT and Morrbid-/- LSK cells (CD398

, CD19-, B220-, NK1.1-, CD4-, CD8-, CD11b-, CD11c-, Ter119-, Ly6G-, Sca-1+, ckit+) were mixed 1:1 and transferred as described above into lethally irradiated WT
hosts.

Bone marrow derived eosinophils
Bone marrow was isolated and cultured as previously described(Dyer et al., 2008).
Briefly, unfractionated bone marrow cells were cultured with 100 ng/ml stem cell
factor (SCF) and 100 ng/ml FLT3-Ligand (FLT3-L). At day 4, the media was
replaced with media containing 10ng/ml interleukin (IL-5). Mature bone marrow
derived eosinophils were analyzed between day 10-14.

Bone marrow derived macrophage cultures
Bone marrow cells were isolated and cultured in media containing recombinant
murine M-CSF (10 ng/ml) for 7-8 days. On day 7-8, cells were re-plated for use in
experimental assays. Bone marrow derived macrophages were stimulated with
LPS (250 ng/mL) for the indicated periods of time.

ChIRP-qPCR
Briefly, 40 x 107 Immortalized bone marrow derived macrophages were fixed with
40 ml of 1% glutaraldehyde for 10 min at room temperature. Crosslinking was
quenched with 0.125M glycine for 5 min. Cells were rinsed with PBS, pelleted for
4 min at 2000g, snap frozen in liquid nitrogen, and stored at -80°C. Cell pellets
were thawed at room temperature and resuspended in 800 μl of lysis buffer (50
99

mM Tris-HCl pH 7.0, 10 mM EDTA, 1% SDS, 1 mM PMSF, cOmplete protease
inhibitor (Roche), 0.1 U/ml Superase In (Life Technologies)). Cell suspension was
sonicated using a Covaris S220 machine (Covaris; 100 W, duty factor 20%, 200
cycles/burst) for 60 minutes until DNA was in the size range of 100–500 bp. After
centrifugation for 5 min at 16100g at 4°C, the supernatant was aliquoted, snap
frozen in liquid nitrogen, and stored at -80°C. 1 mL of chromatin was diluted in 2
mL hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris HCl pH 7.0, 1 mM
EDTA, 15% formamide) and input RNA and DNA aliquots were removed. 100
pmoles of probes (Supplementary Table 1) were added and mixed by rotation at
37°C for 4 hr. Streptavidin paramagnetic C1 beads (Invitrogen) were equilibrated
with lysis buffer. 100 μl washed C1 beads were added, and the entire reaction was
mixed for 30 min at 37°C. Samples were washed five times with 1 ml of washing
buffer (SSC 2x, 0.5% SDS and fresh PMSF). 10% of each sample was removed
from the last wash for RNA isolation. RNA aliquots were added to 85 μl RNA PK
Buffer pH 7.0 ( 100mM NaCl, 10mM TrisCl pH 7.0, 1mM EDTA, 0.5% SDS, 0.2U/ul
Proteinase K) and incubated for 45 min with end-to-end shaking. Samples were
spun down, and boiled for 10 min at 95°C. Samples were chilled on ice, added to
500uL

TRizol,

and

RNA

was

extracted

according

to

manufacturer’s

recommendations. Equal volume of RNA was reversed transcribed and assayed
by qPCR using Hprt and Morrbid-exon1-1 primer sets (Supplementary Table 1).
DNA was eluted from remaining bead fraction twice using 150 μL DNA elution
buffer (50mM NaHCO3, 1%SDS, 200mM NaCl, 100 μg/mL RNase A, 100U/mL
RNase H) incubated for 30 min at 37°C. DNA elutions were combined and treated
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with 15μL (20mg/mL) Proteinase K for 45min at 50°C. DNA was purified using
Phenol:Chloroform:Isoamyl and assayed by qPCR using the indicated primer
sequences (Supplementary Table 1).

shRNA generation and transduction
shRNAs of indicated sequences (Supplementary Table 1) were cloned into
pGreen shRNA Cloning and Expression Lentivector. Psuedotyped lentivirus was
generated as previously described, and 293T cells were transfected with a
packaging plasmid, envelop plasmid, and the generated shRNA vector plasmid
using Lipofectamine 2000.

Virus was harvested 14-16hrs and 48hrs post

transfection, combined, 0.4μm filtered, and stored at -80°C. For generation of in
vivo bone marrow (BM) chimeras, virus was concentrated 6X by ultra
centrifugation using a Optiprep gradient (Axis-Shield).

For transduced BM-derived eosinophils, cultured BM cells on day 3 of previously
described culture conditions were mixed 1:1 with indicated lentivirus and
spinfected for 2hrs at 260 x g at 25°C with 5 μg/mL polybrene. Cultures were
incubated overnight at 37°C, and media was exchanged for IL-5 containing media
at day 4 of culture as previously described(Dyer et al., 2008). Cells were sorted for
GFP+ cells on day 5 of culture, and then cultured as previously described for
eosinophil generation. Cells were assayed on day 11 of culture.
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For transduced in vivo BM chimeras, BM cells were cultured at 2.5×106 cells/mL
in mIL-3 (10 ng/mL) mIL-6 (5 ng/mL) and mSCF (100 ng/mL) overnight at 37°C.
Culture was readjusted to 2 mL at 2.5×106 cells/mL in a 6 well plate, and spinfected
for 2hrs at 260 x g at 25°C with 5 μg/mL polybrene. Cells were incubated overnight
at 37°C. On the day prior to transfer, recipient hosts were irradiated twice with 5
Gy 3 hours apart. Mice were analyzed between 4 and 5 weeks following transfer.

Locked nucleic acid knock-down
Bone marrow-derived macrophages (BMDMs) were transfected with pooled
Morrbid or scrambled locked nucleic acid (LNA) antisense oligonucleotides of
equivalent total concentrations using Lipofectamine 2000. Morrbid LNA pools
contained Morrbid LNA 1-4 sequences at a total of 50 or 100 nM (Supplementary
Table 1). After 24 hours, the transfection media was replaced. The BMDMs were
incubated for an additional 24 hours and subsequently stimulated with LPS (250
ng/mL) for 8-12 hours.

Eosinophils were derived from mouse BM as previously described. On day 12 of
culture, 1–2 x 106 eosinophils were transfected with 50 nM of Morrbid LNA 3 or
scrambled LNA (Supplementary Table 1) using TransIT®-oligo according to
manufacturer’s protocol. RNA was extracted 48 hours post transfection.

Morrbid promoter deletion
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Guide–RNAs targeting the 5’ and 3’ flanking regions of the Morrbid promoter were
cloned into Cas9 vectors pSPCas9(BB)-2A-GFP(PX458) (Addgene plasmid
#48138) and pSPCas9(BB)-2A-mCherry (a generous gift from Dr. Stitzel lab, JAXGM) respectively. gRNA sequences are listed in Supplementary Table 1. The
cloned Cas9 plasmids were then transfected into RAW 264.7, a murine
macrophage cell line using Lipofectamine 2000 according to manufacturer’s
protocol. Forty–eight hours post transfection the double positive cells expressing
GFP and mcherry, and the double negative cells lacking GFP and mcherry were
sorted. The bulk sorted cells were grown in a complete media containing 20% FBS,
assayed for deletion by PCR, as well as for Morrbid and Bcl2l11 transcript
expression by qPCR. RAW 264.7 cells were obtained from ATCC and were tested
for mycoplasma contamination.

Ex vivo cytokine stimulation
Bone marrow (BM)-derived eosinophils, or neutrophils or Ly6Chi monocytes
sorted from mouse BM, were rested for 4-6 hours at 37°C in complete media. Cells
were subsequently stimulated with IL-3 (10ng/mL, Biolegend), IL-5 (10ng/mL,
Biolegend), GM-CSF (10ng/mL, Biolegend), or G-CSF (10ng/mL, Biolegend) for 46 hours. RNA was collected at each timepoint using TRIzol (Life Technologies).

GSK126 treatment
WT and Bcl2l11-/- bone marrow (BM)-derived eosinophils were generated as
previously described(Dyer et al., 2008).
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On day 8 of culture, the previously

described IL-5 media was supplemented with the indicated concentrations of the
EZH2 specific inhibitor, GSK126 (Toronto Research Chemicals).

Media was

exchanged for fresh IL-5 GSK126 containing media every other day. Cells were
assayed for numbers and cell death by flow cytometry ever day for 6 days following
GSK126 treatment.

RNA extraction, cDNA synthesis, and quantitative RT-PCR
Total RNA was extracted from TRIzol (Life Technologies) according to the
manufacturer's instructions. Gycogen (ThermoFisher Scientific) was used as a
carrier.

Isolated

RNA

was

quantified

by

spectophotemetry,

and

RNA

concentrations were normalized. cDNA was synthesized using SuperScript II
Reverse Transcriptase (ThermoFisher Scientific) according to the manufacturer’s
instructions. Resulting cDNA was analyzed by SYBR Green (KAPA SYBR Fast,
KAPABiosystems) or Taqman based (KAPA Probe Fast, KAPABiosystems) using
indicated primers. Primer sequences are listed in Supplementary Table 1. All
reactions were performed in duplicate using a CFX96 Touch instrument (BioRad)
or ViiA7 Real-Time PCR instrument (ThermoFischer Scientific).

RNA-seq and conservation analysis
Reads generated from mouse (Gr1+) granulocytes (previously published
GSE53928), human neutrophils (previously published GSE70068), and bovine
peripheral blood leukocytes (previously published GSE60265) were filtered,
aligned to the corresponding host genome using STAR. Reads mapping around
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the Morrbid locus were visualized. For visualization of Morrbid’s high level of
expression in short-lived myeloid cells, reads from sorted mouse eosinophils
(previously published GSE69707), were filtered, aligned to mm9 using Tophat2,
normalized using RPKM, and gene expression was plotted in descending order.
For each human sample corresponding to the indicated stimulation conditions, the
number of reads mapping to the human MORRBID locus per total mapped reads
was determined.

For conservation across species, the genomic loci and surrounding genomic
regions for the species analyzed were aligned with mVista and visualized using
the rankVista display generated with mouse as the reference sequence. Green
highlights annotated mouse exonic regions and corresponding regions in other
indicated species.

CD8 T cell RNA-seq
Sorted CD62L+CD44lo WT and Morrbid-/- splenic CD8 T cells were either rested
or stimulated for 6 hours at 1x106 cells/mL using 1μg/mL plate-bound αCD3 (1452C11), 1μg/mL soluble αCD28 (37.51) with and without 20ng/mL recombinant IFNβ1 (Biolegend). RNA was harvested as previously described previously using the
RNeasy kit (Qiagen). Sequencing libraries were generated using the SMARTer
Stranded Total RNA Sample Prep Kit Hi Mammalian kit (Takara). Library quality
and concentration were assessed by TapeStation and qPCR respectively. Pairedend 75 base-pair reads were sequenced on the NextSeq500 machine with the V2
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chemistry platform as recommended by Illumina. Reads were quality filtered,
aligned to mm10 using STAR, and normalized using DESeq2. Differential
expression was determined by DESeq2.

Gene-set enrichment analysis (GSEA) was performed using Broad Institute
software as previously described (Henao-Mejia et al., 2013). For the impact of
Bcl2l11-deficiency, a custom gene set was generated from GSE41978 of the top
100 most significantly overexpressed genes in Bcl2l11-/- OTI CD8 T cells at day 6
following L. Monocytogenes-OVA challenge. For AKT-mTOR signaling, the curate
REACTOME_PI3K_AKT_ACTIVATION was used.

RNA fluorescence in situ hybridization
Single molecule RNA fluorescence in situ hybridization (FISH) was performed as
previously described. A pool of 44 oligonucleotides (Biosearch Technologies)
were labeled with Atto647N (Atto-Tec). For validation purposes, we also labeled
subsets consisting of odd and even numbered oligonucleotides with Atto647N and
Atto700, respectively, and looked for colocalization of signal. We designed the
oligonucleotides using the online Stellaris probe design software.

Probe

oligonucleotide sequences are listed in Supplementary Table 1. Thirty Z sections
with a 0.3-μm spacing were taken for each field of view. We acquired all images
using a Nikon Ti-E widefield microscope with a 100x 1.4NA objective and a Pixis
1024BR cooled CCD camera. We counted the mRNA in each cell by using custom
image processing scripts written in MATLAB.
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Cell fractionation
For nuclear and cytoplasmic fractionation, 5 x 106 bone marrow-derived
macrophages (BMDMs) were generated as previously described and stimulated
with 250 ng/mL LPS for 4 hours. Cells were harvested and washed once with cold
PBS. Cells were pelleted, resuspended in 100 μL cold NAR A buffer (10 mM
HEPES pH 7.9; 10mM KCl; 0.1 mM EDTA; 1X cOmplete EDTA-free protease
inhibitor, Sigma; 1mM DTT, 20mM β-glycerophasphate; 0.1 U/μL SUPERaseIn,
Life Technologies), and incubated at 4°C for 20 min. 10 μL 1% NP-40 was added,
and cells were incubated for 3 min at room temperature. Cells were vortexed for
30 seconds, and centrifuged at 6000 rpm for 1.5 min at 4°C. Supernatant was
removed, centrifuged at full speed for 90 min at 4°C, and remaining supernatant
was added to 500 μL Trizol as the cytoplasmic fraction. The original pellet was
washed 4 times in 100 μL NAR A with short spins of 8500 rpm for 1 min. The pellet
was resuspended in 50 μL NAR C (20 mM HEPES pH 7.9; 400mM NaCl; 1mM
EDTA, 1X cOmplete EDTA-free protease inhibitor, Sigma; 1mM DTT, 20mM βglycerophasphate; 0.1 U/μL SUPERaseIn, Life Technologies).

Cells were

vortexed every 3 min. for 10 sec for a total of 20 minutes at 4°C. The sample was
centrifuged at maximum speed for 20 minutes at room temperature. Remaining
supernatant was added to 500 μL Trizol as the nuclear fraction.

Equivalent

volumes of cytoplasmic and nuclear RNA were converted to cDNA using gene
specific primers and Super Script II RT (Life Technologies). Fraction was assessed
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by qPCR for Morrbid-exon1-1 and other known cytoplasmic and nuclear
transcripts. Primer sequences are listed in Supplementary Table 1.

For cytoplasmic, nuclear, and chromatin fractionation, cell fractions were
harvested as described previously, with a few modifications. Briefly, 5-10 x 106
immortalized macrophages were activated with 250 ng/mL LPS (Sigma) for 6
hours at 37°C. Cells were washed 2X with PBS, and then resuspended in 380 μl
ice-cold HLB (50mM Tris-HCl pH7.4, 50mM NaCl, 3mM MgCl2, 0.5% NP-40, 10%
glycerol), supplemented with 100 U SUPERase In RNase Inhibitor (Life
Technologies). Cells were vortexed 30 seconds and incubated on ice 30 minutes,
followed by a final 30 second vortex and centrifugation at 4°C for 5 minutes x
1000g. Supernatant was collected as the cytoplasmic fraction. Nuclear pellets
were resuspended by vortexing in 380 μl ice-cold MWS (50 mM Tris-HCl pH7.4,
4mM EDTA, 0.3M NaCl, 1M Urea, 1% NP-40) supplemented with 100 U
SUPERase In RNase Inhibitor. Nuclei were lysed on ice for 10 minutes, vortexed
for 30 seconds, and incubated on ice for 10 more minutes to complete lysis.
Chromatin was pelleted by centrifugation at 4°C for 5 minutes x 1000g.
Supernatant was collected as the nucleoplasmic fraction. RNA was harvested as
described previously and cleaned up using the RNeasy kit (Qiagen). Equivalent
volumes of cytoplasmic, nucleoplasmic, and chromatin-associated RNA were
converted to cDNA using random hexamers and Super Script III RT (Life
Technologies). Fraction was assessed by qPCR for Morrbid-exon1-2 and other
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known cytoplasmic and nuclear transcripts. Primer sequences are listed in
Supplementary Table 1.

Copy number analysis
Morrbid cDNA was cloned into reference plasmid (pCDNA3.1) containing a T7
promoter. The plasmid was linearized and Morrbid RNA was in vitro transcribed
using the MEGAshortscript T7 kit

(Life Technologies) according to the

manufacturer’s recommendations, and purified using the MEGAclear kit

(Life

Technologies). RNA was quantified using spectrophotometry and serial dilutions
of Morrbid RNA of calculated copy number were spiked into Morrbid-deficient RNA
isolated from Morrbid-deficient mouse spleen. Samples were reverse transcribed
in parallel with WT sorted neutrophil RNA and B cell RNA isolated from known cell
number using gene specific Morrbid primers, and the Morrbid standard curve and
WT neutrophils and B cells were assayed using qPCR with Morrbid-exon 1 primer
sets (Supplementary Table 1)

Bromodeoxyuridine incorporation assay
In Chapter 2, cohorts of mice were given a total of 4 mg Bromodeoxyuridine (BrdU;
purchased from Sigma Aldrich) in 2 separate intraperitoneal (I.P.) injections 3 hrs
apart and monitored over the subsequent 5 days, unless otherwise noted. For
analysis cells were stained according to manufacturer protocol (BrdU Staining Kit,
ebioscience; anti-BrdU, Biolgend). A one-phase exponential curve was fitted from
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the peak labeling frequency to 36hrs post peak labeling within each genetic
background, and the half-life was determined from this curve.
In Chapter 3, CD8 T cells, 1000 WT P14 CD45.1+CD45.2+ and 1000 Morrbid-/P14 CD45.2+ were cotransferred 1:1 into WT CD45.1+ hosts that were infected 24
hours later with LCMV Cl13. 1 mg BrdU was injected at either 84 hours or 108
hours post infection, and mice were sacrificed 12 hours post BrdU injection.
CD8 T cell in vitro effector differentiation
Splenic WT and Morrbid-/- CD8 T cells were either isolated by negative selection
(StemCell Technologies) or sorted for naïve (CD62L+CD44lo) CD8 T cells as
indicated. These cells were stimulated overnight with 1 μg/mL soluble αCD3 (1452C11), 0.5 μg/mL αCD28 (37.51), 100U/mL recombinant hIL-2 (Peprotech), and
20ng/mL IFN-β1 (Biolegend). The following day media was exchanged for media
containing only hIL-2 and IFN-β at the concentrations above, and cells were kept
in culture for an additional 48 hours. During culture, cells were maintained at a
density of 1 x 106/mL.

Rapamycin treatment
In vitro, WT P14 and Morrbid-/- P14 CD8 T cells were negatively selected from
spleen (StemCell Technologies), plated at 1 x 106 cells/mL, treated with the
indicated dose of rapamycin for 1 hour, and subsequently stimulated for 3 hours
with PMA/I in the presence of the same indicated concentration of rapamycin and
Brefeldin A. Cytokine production was assessed by flow cytometry.
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In vivo, 250 WT P14 CD45.1+CD45.2+ and 250 Morrbid-/- P14 CD45.2+ were
cotransferred 1:1 into WT CD45.1+ hosts that were infected 24 hours later with
LCMV Cl13. Hosts were intraperitoneally injected with 75μg/kg of rapamycin daily
beginning the day of adoptive transfer through day 7 post infection.

Seahorse metabolic analysis
In vitro differentiated effector WT P14 and Morrbid-/- P14 CD8 T cells were
generated as described above and assayed using modified XF Cell Mito Stress kit
or Glycolysis Stress kit (Seahorse Bioscience). Briefly, these cells were plated on
Cell-Tak (Corning) coated 96-well polystyrene Seahorse plates, equilibrated for 1
hour at 37°C and assessed for OCR and ECAR after the addition of oligomycin (1
µM), FCCP (1.5µM), etomoxir (200µM) or glucose (10mM), 2-DG (50mM) and
antimycin A/rotenone (1µM/0.1µM).

Human samples
Human subject cohort 1
Study subjects were recruited and consented in accordance with the University of
Pennsylvania Institutional Review Board. Peripheral blood was separated by
Ficoll-Paque density gradient centrifugation, and the mononuclear cell layer and
erythrocyte/granulocyte pellet were isolated and stained for fluorescenceassociated cell sorting as previously described. Neutrophils (Live, CD16+, F4/80int,
CD3-, CD14-, CD19-), Eosinophils (Live, CD16-, F4/80hi, CD3-, CD14-, CD19-), T
cells (Live, CD3+, CD16-), Monocytes (Live, CD14+, CD3-, CD16-, CD56-), NK
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cells (Live, CD56+, CD3-, CD16-, CD14-), B cells (Live, CD19+, CD3-, CD16-,
CD14-, CD56-).

Human subject cohort 2
Samples from human subjects were collected on NIAID IRB-approved research
protocols to study eosinophilic disorders (NCT00001406) or to provide controls for
in vitro research (NCT00090662). All participants gave written informed consent.
Eosinophils were purified from peripheral blood by negative selection and frozen
at -80oC in TRIzol (Life Technologies, Carlsbad, CA). Purity was >97% as
assessed by cytospin. RNA was purified according to the manufacturer's
instructions. Expression analysis by qPCR was performed in a blinded manner by
an individual not involved in sample collection or coding of these of these samples.
Plasma IL-5 levels were measured by suspension array in multiplex (Millipore, St.
Charles, MO). The minimum detectable concentration was 0.1 pg/mL.
Abbreviations for HES subtypes are Familial HES (FHES), PDGFRA+ positive
HES (PDGFRA), episodic angioedema and eosinophilia (EAE), lymphocytic
variant HES (LHES), HES of undetermined significance (HEus), and parasitic
infection (PARA).

Statistics
Samples sizes were estimated based on our preliminary phenotyping of Morrbiddeficient mice. Preliminary cell number analysis of eosinophils, neutrophils, and
Ly6Chi monocytes suggested that there were very large differences between WT
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and Morrbid-deficient samples, which would allow statistical interpretation with
relatively small numbers.

No animals were excluded from analysis.

All

experimental and control mice and human samples were run in parallel to control
for experimental variability and were not randomized. Experiments corresponding
to Fig. 2.6d-f and Fig. 2.8c-f were performed and analyzed in a single-blinded
manner. All other experiments were not blinded. Correlation was determined by
calculating the Spearman correlation coefficient.

Half-life was estimated by

calculating the one-phase exponential decay constant from the peak of labeling
frequency to 36 hours post peak labeling. P values were calculated using a twoway t test, Mann-Whitney U test, one-way ANOVA with Tukey post hoc analysis,
Kaplan-Meier Mantel-Cox test, and FDR as indicated. FDR was calculated using
DESeq2 or GSEA algorithms. All error bars indicate mean plus and minus the
standard error of mean (SEM).

Accession codes:
Primary accessions
Gene Expression Omnibus
GSE85073
Secondary accessions
Gene Expression Omnibus
GSE49435
GSE53928
GSE70068
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GSE60265
GSE69707
GSE41978
GSE88987
GSE71643
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